CEO GE Vernova Scott Strazik uvedl, že zakázková náplň má dosáhnout 200 miliard USD velmi brzy v roce 2027. Zároveň čeká růst marží ve všech třech segmentech a zlepšení ziskovosti ve větrné energetice.
GE Vernova's (GEV -1.25%) CEO, Scott Strazik, recently gave a presentation at a Morgan Stanley conference, and his remarks were bullish on the stock and the company's future prospects. It was a series of subtly positive comments on the business that fell short of a guidance hike, but gave investors plenty of reason to raise earnings expectations. Here's why.
Image source: Getty Images.
What Scott Strazik said For reference, GE Vernova operates out of three segments: power (mainly gas turbine equipment and services), responsible for $2.9 billion in earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2025; electrification (mainly electrical grid solutions), responsible for $1.4 billion in EBITDA in 2025; and finally wind (mainly onshore wind turbines), which lost $598 million in EBITDA in 2025.
Strazik pulled forward expectations for the company's backlog to hit $200 billion in 2027, moving it to "very early in 2027." He also noted that "$200 billion is a very humble milestone on the trajectory we see toward growing to a much larger and more profitable business." Within power, he noted that GE Vernova had 40 gigawatts (GW) of orders in the first half and that the current guidance is for 20 GW in the second half, but "Now 20 gigawatts is likely to prove to be conservative for the second half of the year." Strazik affirmed that all three segments would see margin growth in their 2026 backlog, with GE Vernova reaching a "profitability pivot point" in wind.
Premium Feature
Moneyball Superscore
81/100
Today's Change
(
-1.25
%) $
-12.00
Current Price
$
950.49
What it all means for investors The first three points clearly indicate that orders and backlog momentum for the overall company and power are improving, with no signs of slowing. Moreover, the commentary that $200 billion is a "humble" milestone suggests GE Vernova investors should raise expectations for the company's backlog. Moreover, it's clear there's upside potential for power orders in the second half, and investors should watch what Strazik says in the upcoming third-quarter results presentation.
However, the most interesting point is the affirmation that backlog margin is growing, because a growing backlog combined with rising profitability in that margin implies margin expansion down the line.
Strazik even broke out the expected backlog margin expansion as "larger" in 2026 than the double-digit expansion in 2025. The margin in the electrification backlog will be modest, but there's "a healthy positive change in margin and backlog in wind."
While there's no guarantee the wind segment will start generating earnings again in 2027, GE Vernova appears to be successfully working through the loss-making offshore wind contracts it previously took on. The wind power end-market outlook remains soft, but GE Vernova's profitability in it is turning around, and Strazik argued it has an opportunity to repower its existing installed base.
What's next for GE Vernova? Investors are likely to see improving orders, backlog, and margin momentum in gas turbines driven by artificial intelligence data center demand. Electrification orders (up 76% in the first half of 2026) and backlog (up 64% in the second quarter) are booming, and new products will soon be added to the order book. And wind profitability is turning around. All of these point to a bright future for GE Vernova.
Study met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific antibody
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo. The findings were shared today in an oral presentation at the 35th European Academy of Dermatology and Venereology (EADV) Annual Congress in Vienna, Austria.
Tilrekimig is an investigational, potential first-in-class trispecific antibody that simultaneously inhibits upstream and downstream drivers of type 2 inflammation through concurrent high-affinity binding to interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP). By directly blocking TSLP together with its downstream effectors, tilrekimig is designed to provide broader cytokine pathway coverage and potentially more durable clinical responses. Tilrekimig is also designed to have an extended half-life of about 37 days, which is anticipated to support monthly administration.
“Tilrekimig is a promising investigational medicine in Pfizer’s inflammation and immunology pipeline as we seek to pursue next-generation biologics that address persistent unmet medical needs. The compelling efficacy and tolerability demonstrated in this Phase 2 study validate this multi-pathway, trispecific approach and suggest that tilrekimig has the potential to raise the bar beyond current standard-of-care biologics. Building on these promising findings, we have initiated Phase 3 trials of tilrekimig in atopic dermatitis and asthma, and we are advancing a Phase 2b/3 study in COPD.”
“Systemic treatment in moderate-to-severe atopic dermatitis has moved from broad immunosuppression to targeted therapy, and that shift has meaningfully changed what we can offer patients. But atopic dermatitis is driven by several inflammatory signals, and a substantial proportion of patients still live with persistent itch and extensive skin involvement. The Week 16 results presented today are meaningful at this stage of development, with tilrekimig’s tolerability profile supporting continued study in a larger patient population.”
- Eric Simpson, M.D., M.C.R., Department of Dermatology, Oregon Health & Science University
Detailed Phase 2 Study Results at Week 16
The ongoing Phase 2 trial is evaluating adult patients with moderate-to-severe AD. Data presented at EADV reflect the first two stages of the study, which evaluated biologic-naïve patients: Stage 1 evaluated subcutaneous tilrekimig 450 mg every two weeks (Q2W) versus placebo. Stage 2 was a dose-ranging evaluation of tilrekimig 400 mg, 200 mg, or 50 mg every four weeks (Q4W) versus placebo. The results presented at EADV build upon previously announced topline results. Primary Endpoint (EASI-75 at Week 16): In Stage 1, 62.5% of patients receiving tilrekimig 450 mg Q2W achieved EASI-75, compared to 19.9% in the placebo group (p=0.0008). In Stage 2, 58.5% (400 mg Q4W), 61.0% (200 mg Q4W), and 47.8% (50 mg Q4W) of patients receiving tilrekimig achieved EASI-75, an absolute improvement of 49.4%, 51.9%, and 38.7%, respectively, compared to 9.1% for placebo (all p<0.003). Key Secondary Endpoint: vIGA 0/1 (Clear/Almost Clear skin with ≥2-point improvement): In Stage 1, 30.3% of patients in the 450 mg Q2W group achieved vIGA 0/1 (vs 11.8% for placebo; p=0.0251) In Stage 2, 26%–27% of patients across the Q4W groups achieved vIGA 0/1 (vs 0% for placebo; all p<0.006). Exploratory Endpoint: Itch Reduction (PP-NRS4): In an exploratory analysis, greater proportions of patients receiving tilrekimig achieved a ≥4-point reduction in weekly average Peak Pruritus Numerical Rating Scale compared to placebo, with treatment differences of 35.3% (42.5% vs 7.2%) in the 400 mg Q4W group and 43.6% (50.8% vs 7.2%) in the 200 mg Q4W group. Safety: Tilrekimig was well-tolerated, with no dose-dependent safety signals, with treatment-emergent adverse event (TEAE) rates comparable between treatment and placebo groups. In Stage 1, TEAEs were reported in 46.7% of patients receiving tilrekimig 450 mg Q2W versus 28.9% of patients receiving placebo. In Stage 2, TEAEs were reported in 42.2%, 47.7%, and 47.8% of patients receiving tilrekimig 400 mg, 200 mg, and 50 mg Q4W, respectively, versus 52.2% of patients receiving placebo. In doses up to 400 mg of tilrekimig Q4W, the observed frequency of conjunctivitis and injection-site reactions in this study was lower than rates reported with IL-4 receptor alpha inhibitors and comparable to placebo. There were no serious adverse events related to tilrekimig in both stages 1 and 2. About the Tilrekimig Clinical Trial Program
The Phase 2 study is an ongoing randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
The Phase 3 pivotal program for tilrekimig is underway, with patients dosed in three Phase 3 studies: two in atopic dermatitis — including one with dupilumab as an active comparator — and one in asthma. Pfizer is also studying tilrekimig in an ongoing Phase 2b/3 study in chronic obstructive pulmonary disease (COPD).
Continuing Pfizer’s Commitment to Inflammation and Immunology Conditions
These results build on Pfizer’s ongoing commitment to advancing care for people living with immune-mediated skin conditions. Pfizer currently offers three approved medicines across atopic dermatitis and alopecia areata and continues to invest in a growing dermatology pipeline focused on addressing unmet needs for patients across these conditions.
Pfizer is presenting more than 30 accepted abstracts across its dermatology portfolio at the 35th EADV Congress, spanning atopic dermatitis, alopecia areata, and nonsegmental vitiligo.
Also in atopic dermatitis, Pfizer will present a late-breaking exploratory analysis of serum protein biomarkers from the Phase 3 JADE COMPARE study of CIBINQO (abrocitinib), alongside a final integrated safety analysis of 3,850 patients with up to 6.5 years of exposure. In nonsegmental vitiligo (NSV), Pfizer will present Phase 3 results from the TRANQUILLO program evaluating LITFULO (ritlecitinib) as an investigational medicine in the largest Phase 3 program to date studying an oral systemic therapy in NSV. In alopecia areata, Pfizer plans to share long-term Phase 3 data showing clinically meaningful improvements in scalp hair regrowth with LITFULO through five years, with no new safety signals observed. Pfizer has also initiated a pivotal study evaluating LITFULO for the treatment of moderate alopecia areata. For more information on Pfizer’s Commitment to Immunology and Inflammation, please visit: Inflammation & Immunology | Pfizer.
For more information on Tilrekimig and the trispecific program, please visit: Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis | Pfizer.
About Atopic Dermatitis
Atopic dermatitis is more than “just a rash.” It is a chronic Type 2 (Th2) inflammatory skin condition, affecting people of all ages and genders around the world.1,2 Atopic dermatitis is the most common form of eczema, and sometimes the terms are used interchangeably.3 The most frequent symptom of atopic dermatitis is itchy skin, which can lead to rashes, pain, and poor sleep.3 The condition can be debilitating, disrupting patients’ daily lives, and negatively affecting their emotional well-being. Many patients do not experience a clinically meaningful response to currently available treatments, signaling a critical need for further innovation in this class of medicines.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at www.facebook.com/Pfizer/.
Disclosure Notice
The information contained in this release is as of October 1, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about tilrekimig (PF-07275315), including its potential benefits, the development program for tilrekimig, results from an ongoing Phase 2 trial for tilrekimig in patients with moderate-to-severe atopic dermatitis, the initiation of Phase 3 trials of tilrekimig in atopic dermatitis and asthma and the advancement of a Phase 2b/3 study in COPD, and Pfizer’s ongoing commitment to advancing care for people living with immune-mediated skin conditions and continued investment in a growing dermatology pipeline focused on addressing unmet needs for patients across these conditions, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risks associated with initial, preliminary or interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when applications for tilrekimig may be filed in particular jurisdictions for any potential indications; whether and when any such applications for tilrekimig that may be filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether tilrekimig will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of tilrekimig; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
References
1 Jeskey J, Kurien C, Blunk H, et al. Atopic dermatitis: A review of diagnosis and treatment. J Pediatr Pharmacol Ther. 2024 Dec;29(6):587-603. doi: 10.5863/1551-6776-29.6.587.
2 Choragudi S, Yosipovitch G. Trends in the prevalence of eczema among US children by age, sex, race, and ethnicity from 1997 to 2018. JAMA Dermatol. 2023;159(4):454-456.
3 Chovatiya R. Atopic dermatitis (eczema). JAMA. 2023 Jan 17;329(3):268. doi: 10.1001/jama.2022.21457.
Category: Research and Pipeline
* EASI-75 is the industry standard for measuring how effectively a treatment candidate reduces atopic dermatitis (eczema) severity and extent from baseline.
Sanofi a Regeneron rozšiřují alianci o čtyři nové dlouhodobě působící protilátky; Regeneron dostane 1 mld. USD předem a až 7 mld. USD v milníkových platbách.
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from RegeneronRegeneron to receive $1 billion upfront, with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profitsSanofi and Regeneron to host a conference call for investors and analysts today at 14:00 CET/8:00am ET Paris and Tarrytown, NY, October 1, 2026. Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies' more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world.
“This is a deliberate first step in igniting Sanofi’s innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses,” said Belén Garijo, Chief Executive Officer of Sanofi. “By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi’s long-term future.”
Under the expanded license and collaboration agreement, the companies will co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting interleukin-13 (IL-13), IL-4xIL-13 bispecific, interleukin-4 (IL-4) and interleukin-4 receptor alpha (IL-4Rα). IL-13 antibody REGN20423 is currently in a phase 1 clinical study for atopic dermatitis, and the other three antibodies are expected to enter clinical studies in 2027. Regeneron will also have the option to include in the collaboration Sanofi’s lunsekimig, an investigational bispecific Nanobody® VHH therapy targeting TSLP and IL-13, exercisable upon completion of its phase 3 studies for chronic obstructive pulmonary disease.
“The Regeneron-Sanofi Alliance has been one of the most productive in biopharma history. This agreement builds on that foundation to bring the next generation of immunology medicines to patients even faster,” said Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer of Regeneron. “By expanding our Alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved.”
Under the terms of the agreement, Regeneron will receive an upfront payment of $1 billion from Sanofi, with the potential for development, regulatory and commercial milestone payments of up to an additional $7 billion. The companies will share development and commercialization costs for the new programs and will split future profits from these potential products 50:50 on a global basis. Regeneron will lead research and development activities, and Sanofi will lead global commercial efforts. The existing profit-sharing agreement regarding Dupixent will not change.
“The companies’ clinical and commercial Alliance dates to 2003 and has resulted in multiple approved medicines to date, including Dupixent, which has redefined the standard of care for people with type 2 inflammatory diseases and is now one of the most widely used antibodies for any disease, with over 1.5 million active patients worldwide,” said George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “By combining Regeneron’s world-class scientific discovery and antibody development expertise with Sanofi’s global capabilities and reach, we hope to once again deliver the next wave of innovation in immunology.”
The companies have settled their prior collaboration-related litigation.
Conference call for investors and analysts
Sanofi and Regeneron will host a conference call for investors and analysts today at 14:00 CET/8:00am ET. A presentation will be available for download from the Investor Relations section of sanofi.com and regeneron.com when the conference call starts.
Participants may access the conference call via webcast on the ‘Upcoming Events’ page of Sanofi’s website at https://www.sanofi.com/en/investors/news-events/upcoming-events, tab ‘Presentations' and on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. To participate via telephone, please register in advance at this link.
About Dupixent
Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, and allergic fungal rhinosinusitis in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit
www.Regeneron.com or follow Regeneron on
LinkedIn,
Instagram,
Facebook or
X.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” "attempt," “target,” “project,” "strategy," "strive," "desire," “predict,” “forecast,” “ambition,” “guideline,” "seek," “should,” “will,” "goal," or the negative of these, and similar expressions are intended to identify forward-looking statements.
Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation; trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markest Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.
All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.
Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation the research and clinical programs discussed or referenced in this press release such as those evaluating Regeneron-discovered antibodies targeting interleukin-13 (IL-13), interleukin-4 (IL-4), and interleukin-4 receptor alpha (IL-4Rα) as well as a bispecific antibody targeting IL-4xIL-13; the potential for any license, collaboration, or supply agreement, including Regeneron’s amended license and collaboration agreement with Sanofi discussed in this press release, to be cancelled or terminated without realizing the expected benefits of such agreement; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including based on the amended license and collaboration agreement discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as those referenced above; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as those referenced above) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).
Eli Lilly uvedla, že Foundayo v největší a nejdelší studii u diabetu 2. typu splnilo cíl kardiovaskulární bezpečnosti a snížilo A1C i hmotnost oproti inzulinu glarginu.
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine
In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% lower risk of all-cause death vs. insulin glargine, suggesting the potential for more comprehensive health benefits
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. In the trial, which is the largest and longest study of this medicine in type 2 diabetes to date, Foundayo demonstrated a non-inferior risk of major adverse cardiovascular events (MACE) and improved A1C, weight and other key measures of cardiometabolic health compared with insulin glargine. Results from the trial were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, and simultaneously published in The Lancet.
"For people living with type 2 diabetes, protecting the heart is as important as controlling blood sugar," said Klara Klein, M.D., Ph.D., Assistant Professor of Medicine, University of North Carolina School of Medicine. "ACHIEVE-4 reaffirmed the safety of orforglipron and demonstrated an association with a lower risk of major cardiovascular events and death. These results, paired with the simple administration of a once-daily pill, taken without fasting or water restrictions, could make orforglipron a compelling potential option across the globe."
In the trial, the risk of cardiovascular death, heart attack, stroke, or hospitalization for unstable sudden chest pain (MACE-4) was 16% lower for Foundayo vs. insulin glargine (hazard ratio: 0.84; 95.0% CI: 0.59 to 1.20), meeting the prespecified criteria for demonstrating non-inferiority (upper limit of 95.0% CI of the hazard ratio < 1.8).1 The risk of cardiovascular death, heart attack, or stroke (MACE-3) was 23% lower for Foundayo vs. insulin glargine (hazard ratio: 0.77; 95.0% CI: 0.52 to 1.13). In pre-planned analyses, the risk of cardiovascular death was 53% lower (hazard ratio: 0.47; 95.0% CI: 0.25 to 0.90) and the risk of all-cause death was 57% lower (hazard ratio: 0.43; 95.0% CI: 0.25 to 0.75) for Foundayo vs. insulin glargine.2
In addition to demonstrating cardiovascular safety, Foundayo was associated with meaningful improvements across multiple cardiovascular risk factors. At week 52, participants treated with Foundayo experienced reductions in waist circumference by 7.0 cm, systolic blood pressure by 4.4 mmHg, triglycerides by 18.9%, non-HDL cholesterol by 6.6% and hsCRP, a marker of inflammation, by 38.9%.2 Foundayo was also associated with a slower decline in kidney function, a key contributor to cardiovascular risk, including a 2.8 mL/min/1.73 m² smaller reduction in eGFR and a 27.1% greater reduction in albuminuria compared to insulin glargine.2
ACHIEVE-4 Detailed Results
Foundayo
Insulin Glargine
Primary Endpoint
Time to first occurrence of
MACE-4i
Hazard ratio = 0.84
95.0% CI: 0.59 to 1.20ii
p = 0.336
Key Secondary Endpoints
Time to first occurrence of
MACE-3i
Hazard ratio = 0.77
95.0% CI: 0.52 to 1.13
p = 0.181
Change in A1C from
mean baseline of
8.22% at 52 Weeks iii
-1.6 %
-1.0 %
Estimated treatment difference:
-0.66 (95.0% CI: -0.74 to -0.58)
p <0.001
Change in body
weight from mean
baseline of 90.9 kg
(200.4 lbs; BMI of 32.6 kg/m²) at 52 Weeks iii
-8.8%
(-8.1 kg / -17.9 lbs)
+1.7%
(+1.4 kg / +3.1 lbs)
Estimated treatment difference:
-10.42% (95.0% CI: -10.92 to -9.93)
p < 0.001
Secondary Endpoints at 104 Weeks
Percent of participants achieving A1C ≤6.5%iii, iv
54.6 %
23.8 %
Percent of participants achieving body weight reduction of ≥10%iii, iv
35.9 %
3.4 %
Additional Pre-Planned Analysis
All-cause deathi,iv
Hazard ratio = 0.43
95.0% CI: 0.25 to 0.75
p = 0.002
Cardiovascular deathi,iv
Hazard ratio = 0.47
95.0% CI: 0.25 to 0.90
p = 0.019
iTime to first event analysis using Cox proportional hazard model for CI and log-rank for p-value. All data from randomization to end of the study were included in the analysis.
iiNon-inferiority (upper limit of 95% CI of the hazard ratio < 1.8).
iiiResults of A1C and body weight were based on efficacy estimand.3
ivNot controlled for family-wise type 1 error.
"Foundayo has consistently delivered strong efficacy in type 2 diabetes across our Phase 3 ACHIEVE program," said Thomas Seck, M.D., senior vice president of product development, Lilly Cardiometabolic Health. "In ACHIEVE-4, our largest and longest study of this medicine, Foundayo helped more than half of participants reach an A1C of 6.5% or lower, with durable reductions in A1C and body weight and a favorable overall safety profile. This kind of efficacy reinforces our confidence that Foundayo could change how physicians and patients approach the treatment of type 2 diabetes."
The overall safety and tolerability profile of Foundayo in ACHIEVE-4 was generally consistent with previous trials and with other incretins. The most common adverse events for participants taking Foundayo were nausea, vomiting, diarrhea, decreased appetite, and constipation. During the 52-week minimum treatment period, 10.6% of participants taking Foundayo discontinued treatment due to adverse events.
To further evaluate the impact Foundayo has on cardiovascular outcomes in adults with obesity or overweight with or without type 2 diabetes, Lilly is conducting ATTAIN-OUTCOMES, an ongoing Phase 3 study in adults with established cardiovascular or kidney disease.
About Foundayo (orforglipron)
Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day with no planning around food or drink.
Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
About ACHIEVE-4 and ACHIEVE clinical trial program
ACHIEVE-4 (NCT05803421) is a Phase 3, event-driven, randomized, open-label trial evaluating the efficacy and safety of Foundayo compared with insulin glargine U-100 in adults with type 2 diabetes and obesity or overweight (BMI ≥25 kg/m2) with increased risk of cardiovascular events. The trial randomized 2,749 participants across the U.S., Argentina, Austria, Brazil, Czechia, Germany, Greece, India, Italy, Mexico, Puerto Rico, Romania, Slovakia, South Korea, Spain and Turkey to receive either escalating doses of Foundayo or insulin glargine. The primary objective of the study was to demonstrate that Foundayo was non-inferior in the risk of major adverse cardiovascular events (MACE-4) compared to insulin glargine in adults with type 2 diabetes and obesity or overweight with increased risk for cardiovascular events who have taken at least one and no more than three oral anti-diabetic medications for at least 90 days prior to study start. Study participants had an A1C between ≥7.0% and ≤10.5% (≥7.5% and ≤10.5% if background diabetes medication included a sulfonylurea) and a BMI of ≥25 kg/m2 with stable weight (±5%) for at least 90 days prior to study start. Participants randomized to Foundayo initiated treatment with 0.8 mg once daily and increased the dose every four weeks until reaching a maximum tolerated dose (up to 17.2 mg). The trial was conducted using an investigational formulation of Foundayo at dosages equivalent to Foundayo tablets.
The ACHIEVE Phase 3 global clinical development program for Foundayo began in 2023 and enrolled more than 6,000 people with type 2 diabetes across five global registration trials.
Endnotes
Time to first event analysis using Cox proportional hazard model using all randomized participants exposed to ≥1 dose of study intervention. All-cause death, waist circumference, serum lipids, blood pressure, hsCRP, cardiovascular death and kidney function endpoints were not controlled for family-wise type 1 error. Waist circumference, eGFR, albuminuria, serum lipids, blood pressure and hsCRP were based on efficacy estimand. The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and/or dose modifications) without initiating additional antihyperglycemic medications (>14 days of use). U.S. FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.
Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children. Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. Foundayo may cause serious side effects, including:
Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.
Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.
Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.
Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before taking Foundayo
Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?
How to take
Take Foundayo exactly as your healthcare provider tells you to. Use Foundayo with a reduced-calorie diet and increased physical activity. Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet. If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. Do not take more than 1 tablet per day. If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.
This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.
OG CON BS APR2026
Foundayo™ is a trademark of Eli Lilly and Company.
U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:
obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.
Zepbound may cause serious side effects, including:
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.
Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.
Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.
Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using Zepbound
Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.
Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit https://pregnancyregistry.lilly.com/zepbound. How to take
Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or
have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.
Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.
This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.
ZP CON BS 01SEP2026
Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo (orforglipron) as a potential treatment for adults with type 2 diabetes, potential efficacy and tolerability of Foundayo, and the timeline for future readouts, presentations, and other milestones relating to Foundayo and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that Foundayo will prove to be a safe and effective treatment for type 2 diabetes, that Foundayo will receive additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
JERA, Dell Technologies a RHAELM uzavřely dohodu o vývoji standardizované AI infrastruktury v Japonsku, včetně úvodního hyperscale datového centra za 15 miliard USD v Čibě. Projekt má postupně zahájit provoz v roce 2028 a dosáhnout plné kapacity 400 MW v roce 2029.
Japan's biggest power generator JERA will partner with Dell Technologies (DELL.N) and UK-based AI infrastructure developer RHAELM to accelerate the development of AI infrastructure in Japan, the three companies said on Thursday.
They signed a memorandum of understanding (MoU) to develop a standardised framework for building AI infrastructure at a national scale in Japan, starting with a $15 billion hyperscale data centre in Chiba.
The model will be applied first to a project in Chiba, where Apollo Global Management plans to serve as a strategic investment and financial partner for RHAELM, they said in a statement.
The companies aim to create a standardised, repeatable and scalable model from the outset, reducing the lengthy lead times and complexity involved in developing each project independently.
They aim to establish the model first in Japan and explore opportunities to apply it in other global markets.
In Chiba, JERA will make available land adjacent to its Chiba power station, while RHAELM will develop, construct, operate and finance a 400-megawatt-class hyperscale AI data centre.
The companies aim to begin operating the new data centre in phases in 2028 and reach the full 400 MW capacity in 2029, a JERA official said.
JERA will supply 400 MW of power capacity under a 15- to 25-year agreement, while Dell will provide standardised, rack-scale AI infrastructure.
Energetická skupina Photon Energy oznámila, že opět odkládá zveřejnění výroční zprávy a auditované konsolidované účetní závěrky za rok 2025, přičemž nový termín zatím neurčila.
Společnost původně plánovala zveřejnit výroční zprávu 31. července 2026, termín však posunula na 30. září 2026. Tento první odklad přímo souvisel s přípravou hlasování držitelů zeleného dluhopisu EUR Green Bond 2021/2027 (ISIN: DE000A3KWKY4), kterým firma chtěla předložit mimo jiné změny finančních kovenantů. Výsledek mohl ovlivnit předpoklady pro sestavení účetní závěrky a audit. Dne 1. září 2026 pak představenstvo hlasování bez svolání schůze ukončilo. Společnost obdržela protinávrhy a námitky k procesním aspektům hlasování.
Photon Energy uvedl, že na dokončení statutárního auditu a finalizaci výroční zprávy potřebuje více času. Představenstvo nyní posuzuje upravený harmonogram a nový termín zveřejnění oznámí, jakmile ho stanoví.
Akcie Photon Energy Akcie společnosti Photon Energy (BAAPEN) včera na pražské burze uzavřely na 6,8 Kč.
Zdroj: Photon Energy
Michal Bárta
Fio banka, a.s.
Prohlášení
Související odkazy Photon Energy ruší hlasování držitelů dluhopisů, návrhy by podle společnosti neprošly Photon Energy reportoval výsledky za 2Q a 1H 2026 Photon Energy odkládá kupon i výroční zprávu, věřitele svolává k hlasování o restrukturalizaci Photon Energy: Sadif Investment Analytics zvyšuje cílovou cenu a doporučení Photon Energy zveřejnil výsledky za 1Q
WTW získala regulační souhlas k převzetí plné kontroly nad Al-Futtaim Willis po prodeji 51% podílu společností Al-Futtaim. Firma tím posiluje expanzi v SAE a Saúdské Arábii.
Regulatory approvals from the Central Bank of the UAE (United Arab Emirates) and the Central Bank of Bahrain complete the change in ownership of Al Futtaim Willis.
Complements broader regional expansion underway with growing presence in UAE and Saudi Arabia.
DUBAI, United Arab Emirates, Oct. 01, 2026 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, today confirmed regulatory approval for a change in the ownership of its longstanding joint venture, UAE-based Al-Futtaim Willis (AFW). Following Al-Futtaim’s sale of its 51% stake in the joint venture, WTW will assume full control of the AFW business.
Pamela Thomson-Hall, Head of International at WTW, said: “WTW’s investment strategy remains acutely focused on optimizing the company’s portfolio globally and pursuing scaled and high-growth broking businesses. This investment will enable us to wholly manage our businesses in Dubai and Bahrain going forward . It further strengthens our strategy and enables us to provide clients in the UAE and wider region with better access to our specialist expertise and global placement capabilities. It also enhances our ability to serve our global benefit management clients through a more consistent delivery approach.”
Head of WTW CEEMEA, Eleni Lykoudi, commented: “This change in ownership structure complements WTW’s recent investments in the Kingdom of Saudi Arabia, where the company recently established insurance and reinsurance broking entities. The integration of AFW will allow our local, regional, and global clients to access WTW’s entire portfolio, enhancing our value proposition in the market. All of this speaks to WTW’s commitment to invest in the Middle East and our enhanced client service offering in the region.”
About WTW
At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at www.wtwco.com
Forward Looking Disclaimer
This document contains ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by those laws. You can identify these statements and other forward-looking statements by words such as ‘may’, ‘will’, ‘would’, ‘commit’, ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘intend’, ‘plan’, ‘future’, or similar words, expressions or the negative of such terms or other comparable terminology. These forward-looking statements include, but are not limited to, strategic plans and the future of our business, receipt of regulatory approvals and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. All forward-looking disclosure is speculative by its nature.
There are important risks, uncertainties, events and factors that could cause our actual results or performance to differ materially from those in the forward-looking statements contained in this document, including, but not limited to those described under “Risk Factors” in the Company’s most recent 10-K filing and subsequent filings filed with the SEC. The foregoing list of factors is not exhaustive, and new factors may emerge from time to time that could also affect actual performance and results. Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of these assumptions, and therefore also the forward-looking statements based on these assumptions, could themselves prove to be inaccurate. Given the significant uncertainties inherent in the forward-looking statements included in this document, our inclusion of this information is not a representation or guarantee by us that our objectives and plans will be achieved. Our forward-looking statements speak only as of the date made, and we will not update these forward-looking statements unless the securities laws require us to do so. With regard to these risks, uncertainties and assumptions, the forward-looking events discussed in this document may not occur, and we caution you against unduly relying on these forward-looking statements.
Kyndryl uvedl, že 98 % organizací odložilo modernizaci a pocítilo negativní dopady na byznys. Téměř polovina firem je navíc za plánem, zatímco 10 % už nasadilo agentic AI do produkce.
Global survey reveals how 2,000 business and technology leaders are addressing AI-driven demand across IT elements
Nearly half of organizations are behind schedule despite modernization being a top priority 98% of organizations delayed modernization and experienced negative business impacts As AI reshapes expectations for how technology can deliver results, more organizations are expanding their use of technology than consolidating them Organizations deploying agentic AI are making faster modernization progress and seeing early benefits as AI takes on traditionally challenging tasks , /PRNewswire/ -- Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today released its first global Modernization Report, which found that as organizations expand investments across legacy and modern platforms, modernization increasingly requires business orchestration, not technology consolidation.
"AI is creating new possibilities and raising expectations for the business outcomes technology should deliver," said Martin Schroeter, Chairman and CEO, Kyndryl. "Modernization is about preparing for what comes next, and the leaders making the most progress are investing across their technology environments—strengthening resilience and putting those investments to work where they deliver the greatest value."
Based on insights from 2,000 business and technology leaders across five continents and 12 industries, the research shows how AI is reshaping investment priorities across infrastructure and applications, while also challenging organizations' operating models.
According to the report's findings, the need to adopt AI now outranks priorities to reduce spending, replace legacy systems, or address a shrinking pool of legacy systems expertise. AI is the top driver of increased mainframe and edge computing use, the second-biggest driver for SaaS and private cloud expansion, and the leading reason organizations are upgrading their networks and application portfolios. Every organization with a mainframe now reports plans to deploy AI to the platform.
Together, these trends are creating more complex technology environments and new operational challenges for technology leaders.
Nearly half of respondents said they are behind schedule on their modernization goals. Agentic AI, which can autonomously plan and execute tasks, is emerging as a way to modernize faster. Ten percent of organizations have deployed agentic AI in production for modernization, applying it to typically time- and skills-intensive tasks of dependency mapping, code conversion, and generating documentation. Early adopters reported stronger outcomes, with 67% saying they are ahead of or on track with modernization goals, compared with 51% of other organizations.
The research also highlights what is slowing organizations down. Just 9% said they fully understand their applications' dependencies, and one-quarter say they have large numbers of undocumented applications.
Among other findings, Kyndryl's study shows that:
Modernization has become a business-wide priority, not just a technical one
The findings underscore the growing demands on CIOs, who must advance several priorities at once: AI adoption, cyber resilience, regulatory compliance, operational efficiency, and business growth. Respondents named nine distinct stakeholder groups with control over modernization, from CIOs and CTOs to boards of directors and finance and compliance teams. Modernization has outgrown the IT department and become a board-level business decision. Its growing importance also requires organizations to coordinate decision-making across more stakeholders without sacrificing speed.
Global events shape technology decisions alongside cost and performance
Sovereignty considerations are a growing factor in modernization strategies. While 65% of organizations address sovereignty selectively or primarily through a compliance lens, 63% expect sovereign cloud usage to increase and 55% expect sovereignty and regulatory requirements to place greater demands on their network architectures. The findings suggest that the geographic location of where technology runs is increasingly being shaped by governance and geopolitical considerations alongside performance, cost and innovation.
Complexity keeps compounding
The findings challenge the long-held assumption that digital transformation would lead organizations to gradually migrate toward a single preferred technology environment. Instead, their technology environments are becoming more distributed and complex as they prepare for AI. Mission-critical applications are distributed almost evenly across public cloud, private cloud, mainframe and on-premises environments, creating an increasingly hybrid enterprise. As digital transformation extends across the business, it must be underpinned by strategic, governance, and operational coordination—including a more integrated approach to cyber resilience as AI-driven threats accelerate and broaden.
Read more about Kyndryl's 2026 Modernization Report.
About Kyndryl
Kyndryl (NYSE: KD) is a leading provider of mission-critical enterprise technology services, offering advisory, implementation and managed services across thousands of customer environments in more than 60 countries. The company designs, builds, manages and modernizes the complex information systems that the world depends on every day. For more information, visit www.kyndryl.com.
Cboe plánuje v říjnu 2026 spustit nové binární kontrakty na KPI pro 23 firem, pokud dostane regulační souhlas. Robinhood je nabídne jako první broker pro drobné investory.
Products tied to 23 companies to roll out in October, subject to regulatory approval
, /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), a leading global markets operator and pioneer in equity and index derivatives, today announced at Robinhood's third annual HOOD Summit in Houston, Texas, that it plans to launch a new category of binary contracts tied to company-specific key performance indicators (KPIs), expected in October 2026, subject to regulatory approval. Robinhood will be the first retail broker to offer these products to its clients at launch.
The KPI binary options will provide investors with a new way to take positions on specific company metrics and corporate events through Securities and Exchange Commission (SEC)-regulated products traded on Cboe's registered U.S. securities exchange. This proposed framework differentiates Cboe's products from similar event-based contracts currently traded on designated contract markets (DCMs) and reflects its view that these securities products should be traded within the transparency, oversight and investor protections of the U.S. securities markets, including the benefits of federal preemption of state securities registration requirements.
The planned launch comes amid growing investor demand for products that are intuitive, event-driven and directly based on the companies they follow. Cboe plans to initially list contracts for 23 U.S.-listed companies that represent some of the most actively traded U.S. stocks. Cboe will not charge fees on the KPI binary options through the end of 2026, subject to regulatory review. Robinhood will additionally offer the products with no fees through the end of the year.
JJ Kinahan, Head of Retail Expansion and Alternative Investment Products at Cboe, said: "These KPI contracts are designed to provide exposure to key corporate metrics, giving investors a granular way to trade many of the individual components that are being tracked and driving headlines each quarter. We're pleased to have Robinhood among our first partners in bringing these SEC-regulated products to its client base. As investable event contracts, we believe they will appeal to a broad spectrum of market participants, from systematic traders seeking targeted exposure to retail investors looking to better understand how KPIs can influence a company's performance."
Steve Quirk, Chief Brokerage Officer at Robinhood, said: "Earnings contracts give retail investors another tool to inform their strategies and offer an even more precise way to trade on anticipated company KPIs."
As part of this initiative, Cboe filed an application for temporary registration from the SEC for its U.S. clearinghouse, Cboe Clear U.S., LLC (CCUS), as a Covered Clearing Agency. Subject to regulatory review and approval, CCUS would clear the KPI contracts.
Rob Hocking, Global Head of Derivatives at Cboe, said: "This isn't just about launching a new product, but an example of how Cboe can leverage our strengths across listing, trading and clearing, as well as our history of operating trusted, regulated markets, to help build out the next generation of markets and products. We're particularly excited to expand our U.S. clearing capabilities, which will further strengthen Cboe's competitive position and broaden our ability to support new products – both traditional and non-traditional financial instruments – creating opportunity for even more optionality and innovation."
Following initial registration, CCUS may pursue opportunities, subject to regulatory approval, to expand its clearing services beyond the CFTC-regulated derivatives it clears today to support new products, potentially including tokenized binary security options, reflecting Cboe's broader strategy to expand its U.S. clearing business into new product categories over time.
About Cboe Global Markets
Cboe Global Markets (Cboe: CBOE) is a leading global markets operator with a long history of innovation in equity and index derivatives. Since launching the world's first listed options exchange in 1973, Cboe has pioneered landmark products, including the introduction of S&P 500® index options and the creation of the VIX® Index, the world's leading gauge of market volatility, reshaping how investors manage risk and access opportunity. Today, Cboe operates derivatives, equities, and FX markets, providing trading, clearing, and investment solutions for customers worldwide. To learn more, visit www.cboe.com.
Cboe Media Contacts
Cboe Analyst Contact
Angela Tu
Tim Cave
Kenneth Hill, CFA
+1-646-856-8734
+44 (0) 7593-506-719
+1-312-786-7559
[email protected]
[email protected]
[email protected]
CBOE-C
CBOE-OE
Cboe®, Cboe Global Markets®, and VIX® are registered trademarks and Cboe PlusSM is a service mark of Cboe Exchange, Inc and S&P 500® is a registered trademark of Standard & Poor's Financial Services LLC. All other trademarks and service marks are the property of their respective owners.
Cautionary Statements Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. You can identify these statements by forward-looking words such as "may," "might," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," and the negative of these terms and other comparable terminology. All statements that reflect our expectations, assumptions or projections about the future other than statements of historical fact are forward-looking statements. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from those expressed or implied by the forward-looking statements.
We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Some factors that could cause actual results to differ include: the loss of our right to exclusively list and trade certain index options and futures products; economic, political and market conditions; compliance with legal and regulatory obligations; price and new products and services competition and consolidation in our industry; decreases in trading or clearing volumes, market data fees or a shift in the mix of products traded on our exchanges; legislative or regulatory changes or changes in tax regimes; our ability to protect our systems and communication networks from security vulnerabilities and breaches; our ability to attract and retain skilled management and other personnel; increasing competition by foreign and domestic entities; our business and operational dependence on and exposure to risk from third parties; factors that impact the quality and integrity of our and other applicable indices; our ability to manage our global operations, growth, and strategic acquisitions, wind downs, divestitures, or alliances effectively; increases in the cost of the products and services we use; our ability to operate our business without violating the intellectual property rights of others and the costs associated with protecting our intellectual property rights; our ability to minimize the risks, including our credit, liquidity, market, investment, counterparty, and default risks, associated with operating our clearinghouses; our ability to accommodate trading and clearing volume and transaction traffic, including significant increases, without failure or degradation of performance of our systems; misconduct by those who use our markets or our products or for whom we clear transactions; challenges to our use of open source software code; our ability to meet our compliance obligations, including managing our business interests and our regulatory responsibilities; the loss of key customers or a significant reduction in trading or clearing volumes by key customers; damage to our reputation; the ability of our compliance and risk management methods to effectively monitor and manage our risks; restrictions imposed by our debt obligations and our ability to make payments on or refinance our debt obligations; our ability to maintain an investment grade credit rating; impairment of our goodwill, long-lived assets, investments or intangible assets; the accuracy of our estimates and expectations; and litigation risks and other liabilities. More detailed information about factors that may affect our actual results to differ may be found in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made from time to time with the SEC.
We do not undertake, and we expressly disclaim, any duty to update any forward-looking statement whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
CoreWeave rozšiřuje nabídku o NVIDIA Vera CPU, první procesor navržený pro AI agenty. Firma uvádí, že v testech zkrátila spouštění sandboxů o více než 3× oproti x86 CPU.
SAN FRANCISCO--(BUSINESS WIRE)--CoreWeave Inc. (Nasdaq: CRWV), The Essential Cloud for AI™, today announced it will expand its compute portfolio with the NVIDIA Vera CPU, the first CPU designed for AI agents, to meet the needs of new workloads. The news was shared during Fully Connected, CoreWeave’s AI cloud conference, which brings together more than 4,500 customers, partners, developers, and AI leaders to share how they are building and running AI in production.
Agentic AI operates through a continuous AI loop of run, observe, curate, improve, and evaluate. GPUs power model training and reasoning, while CPUs execute the work surrounding every step: isolated sandboxes, reinforcement learning environments, tool calls, code execution, and data pipelines. Demand for data preprocessing pipelines and reinforcement learning training episodes is bursty and hard to predict. A single step in the loop can demand thousands of environments for an hour, then virtually nothing until the next run.
As post-training and agentic workloads grow, that CPU-intensive work increasingly determines how quickly the AI loop can turn. Infrastructure must provide both the density to support that demand and the flexibility to scale as it changes. On CoreWeave, NVIDIA Vera CPU runs the way the rest of the fleet does: bare metal, under the same platform, consumption models and economics.
“General-purpose infrastructure bottlenecks agentic AI; Vera is the first CPU explicitly designed to accelerate it,” said Chen Goldberg, executive vice president of product & engineering at CoreWeave. “Our platform natively enables Vera with products like CoreWeave Sandboxes out of the box. Teams can instantly spin up thousands of isolated environments, removing operational friction and accelerating the entire AI loop on day one.”
NVIDIA Vera supports the demanding workloads behind agentic AI. A critical measure of performance for agentic AI is how many isolated agent environments a team can run concurrently, and how consistent per-sandbox performance stays as that number climbs. Rack-scale Vera at CoreWeave puts 128 CPUs and 11,264 cores in a single rack, with BlueField-4 DPUs and Spectrum-X Ethernet switching delivering secure, high-performance connectivity between Vera nodes; that’s room for more than 11,000 concurrent environments. Through CoreWeave Sandboxes, these agents can be deployed securely and efficiently, fully hardware-isolated, and situated directly alongside the training jobs they support. In testing, CoreWeave achieved more than 3x faster agent sandbox startup times on NVIDIA Vera CPU compared to an x86 CPU.
“AI infrastructure conversations have centered on accelerators, and agentic systems are changing that," said Ryan Shrout, president & general manager at Signal65. “A growing share of every agent cycle is CPU work, and that share is only going to increase as post-training and agentic deployments scale. What decides whether teams can use that capacity is the platform around it. Running it on bare metal, beside the training fleet, under orchestration that already exists, is where the operational difference shows up.”
CoreWeave consistently delivers industry-leading performance, demonstrated by record-breaking MLPerf benchmark results in inference and training and its position as the only AI cloud to earn the top Platinum ranking in SemiAnalysis ClusterMAX™ three times in a row.
About CoreWeave
CoreWeave is The Essential Cloud for AI™. Built for pioneers by pioneers, CoreWeave delivers a fully integrated platform of technology and teams that enables innovators to move at the pace of innovation, building and scaling AI with confidence. Trusted by 9 of the 10 leading foundation model providers, CoreWeave serves as a force multiplier by combining superior infrastructure performance with deep technical expertise to accelerate human discovery. Established in 2017, CoreWeave completed its public listing on Nasdaq (CRWV) in March 2025.
Eldorado Gold očekává, že Skouries v Řecku a McIlvenna Bay v Kanadě dosáhnou komerční produkce v příštím čtvrtletí. Nové doly mají výrazně zvýšit těžbu zlata i mědi a přinést peněžní tok od roku 2027.
3 High-Momentum Gold Stocks Surging on the Metals RallyEldorado Gold NYSE: EGO said it is approaching a transition from a period of major capital investment to higher production and cash generation, with its Skouries project in Greece and McIlvenna Bay project in Canada expected to reach commercial production in the coming quarter.
In a presentation, Christian said the company has completed the bulk of construction work on the two projects and is shifting its focus toward operational execution. The company expects the new mines to drive a substantial increase in both gold and copper output, while creating a cash-flow inflection beginning in 2027.
Get Eldorado Gold alerts:
Which of these Gold Mining Stocks is Glittering After Earnings?“We’ve just finished two big builds,” Christian said. “Now it’s time to take a pause, take a breather, and focus on the execution and operational excellence.”
New Mines Expected to Add Gold and Copper Production Skouries, Eldorado’s new flagship operation in Greece, is expected to begin production in the next quarter. The project has a projected 20-year mine life and is expected to average roughly 150,000 ounces of gold and 70 million pounds of copper annually over its life.
The company said it has nearly 4.6 million to 4.7 million tonnes of ore stockpiled in front of the Skouries mill, equivalent to about six months of feed. About one-third of the stockpile is sulfide ore, which Christian said will support the ramp-up process. The company has also energized the main substation and is commissioning the first two of six tailings filters.
“Skouries is in a great place,” Christian said, adding that the project is positioned to generate significant cash flow after production begins.
McIlvenna Bay in Saskatchewan has already produced its first copper concentrate in June and zinc concentrate in July, according to the presentation. Eldorado is working toward commercial production during the fourth quarter. The operation has an 18-year mine life, although the company expects to release a new resource estimate for the Tesla zone in the next quarter that could potentially double the mine life.
Together, Skouries and McIlvenna Bay are expected to take Eldorado from essentially no copper output to approximately 110 million pounds of annual copper production, split between roughly 70 million pounds from Skouries and 40 million pounds from McIlvenna Bay.
Portfolio Optimization and Expansion Plans Eldorado operates six assets across Canada, Greece and Türkiye. Its Lamaque mine in Quebec has produced about 200,000 ounces of gold annually, while the company’s two Turkish mines collectively produce more than 200,000 ounces of gold. Olympias in northern Greece currently produces about 60,000 to 70,000 ounces annually and is undergoing an expansion intended to raise output toward 80,000 ounces per year.
The Olympias expansion is expected to enter production in the first quarter of 2027 and ramp up in the second quarter. At Kisladag in Türkiye, the company expects to commission a secondary crusher in the fourth quarter and begin whole-ore agglomeration in the first quarter of 2027. Those upgrades are intended to improve heap-leach efficiency and return Kisladag to roughly 130,000 to 150,000 ounces of annual production.
Longer-term opportunities include potential mill expansions at Lamaque and McIlvenna Bay, subject to feasibility studies expected next year. Eldorado also discussed Perama Hill in northern Greece, where it has submitted an environmental impact assessment. The project is envisioned as a three-gram-per-tonne open-pit mine producing roughly 100,000 ounces of gold annually over an eight-year mine life, although construction would not begin before 2028 at the earliest.
Cash Flow and Capital Returns The company said it ended the prior quarter with approximately $550 million in cash and $1.7 billion in debt, representing net debt of about $1.2 billion. Eldorado also said it has returned nearly $400 million to shareholders through dividends and share buybacks during the past four quarters.
Its quarterly dividend, introduced in the first quarter, totals approximately $20 million per quarter. The company paused buybacks during the latest quarter but said it would consider restarting them if its shares continue to trade at a discount to net asset value after the new projects enter production.
Christian said Eldorado plans to provide updated guidance early in the new year and potentially host a capital-markets day in March to outline future capital-allocation priorities. Dividends and repurchases are expected to be high on the priority list, he said.
The company projected gold-equivalent production could rise from roughly 500,000 ounces to almost 900,000 ounces. It also said it expects free cash flow to exceed $1 billion in 2027 and cited consensus EBITDA of nearly $2.6 billion.
Exploration and Greece Operating Environment Eldorado has committed about $90 million to exploration this year and said future exploration spending could approach $100 million. The company highlighted drilling at the Tesla zone, Lamaque and Olympias as potential sources of mine-life extensions.
During a question-and-answer session, Ralph Profiti, an analyst at Stifel Canada, asked about Eldorado’s operating experience in Greece. Christian said the company has found a skilled workforce and described the permitting process as established, citing groundwork completed for the Skouries permit.
Christian said Skouries could demonstrate mining’s economic contribution to local communities, noting that the project is expected to generate royalty revenue for the surrounding area. He added that the Greek prime minister was expected to visit the site the following week.
About Eldorado Gold (NYSE:EGO)Eldorado Gold Corporation is a Canadian gold mining company engaged in the exploration, development, construction and operation of gold mines. The company produces gold doré and concentrates, with its activities focused on operating and advancing assets in Türkiye, Greece and Canada.
Eldorado Gold's principal producing operations include the Kisladag and Efemcukuru mines in Türkiye, the Olympias mine in northern Greece and the Lamaque mine in Quebec, Canada. The company is also advancing the Skouries project in Greece, a copper-gold development intended to produce both copper concentrate and gold.
The company traces its modern history to the 1990s and has expanded through exploration, mine development and acquisitions, including the acquisition of European Goldfields and Integra Gold.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Eldorado Gold Right Now?Before you consider Eldorado Gold, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eldorado Gold wasn't on the list.
While Eldorado Gold currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Franco-Nevada uvedla, že restart Cobre Panama by mohl během pěti let zvýšit růst zhruba o 45 %. Firma zároveň letos očekává produkci kolem 550 000 GEOs.
MarketBeat Week in Review – 08/10 - 08/14Franco-Nevada NYSE: FNV outlined its approach to profitable growth, citing a focus on return on capital, flexible financing structures and partnerships with operating teams, while highlighting potential production growth from its existing portfolio.
A company representative said Franco-Nevada differentiates itself in the royalty and streaming sector through significant insider ownership and an emphasis on transactions intended to increase shareholder value rather than simply expand the company’s size. The representative said the company seeks to structure financing around the needs of mine operators and views their success as central to its own.
Get Franco-Nevada alerts:
Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?The company said its stock has delivered a compound annual return of 18% since going public 18 years ago, compared with a 9% return for gold over the same period. It attributed its growth to royalty acquisitions, streaming investments in large copper projects and a newer strategy of backing operating teams through broader financing arrangements.
Growth outlook tied to Cobre Panama and portfolio options Franco-Nevada said it expects growth over the next five years and estimated that a restart of Cobre Panama could lift growth to roughly 45% over that period. The company also said its larger portfolio assets could add a combined 222,000 gold-equivalent ounces, or GEOs, annually, although those projects would not necessarily operate at the same time.
Franco-Nevada May Be the Best Way to Play a Commodity SupercycleThe company expects to produce about 550,000 GEOs this year and said production could approach 750,000 GEOs in five years. Over a 10-year horizon, management said the portfolio’s larger optionality assets could help push annual output toward 1 million GEOs.
Franco-Nevada said it has more than $1 billion in cash, significant equity investments and debt capacity, giving it roughly $4.5 billion in available capital for additional royalty and streaming opportunities. It also pointed to its exploration royalty portfolio as a source of organic growth amid higher gold and copper prices and increased industry drilling activity.
Cobre Panama developments Asked about Cobre Panama, the company representative said the direction of developments has been positive. Panama’s government has allowed processing of stockpiles, restarted the site’s power plant and sanctioned a restart of the mills to enable First Quantum Minerals to process existing stockpiles, according to the representative.
First Quantum has increased employment at the site to about 3,000 workers from roughly 1,000 while the mine was in care and maintenance, compared with a full workforce of between 6,000 and 7,000, the representative said. One mill train has been restarted.
The representative said the government has completed an environmental review and established a Council of Ministers to make a recommendation to President José Raúl Mulino. The government has also been consulting local communities, unions and suppliers, with the representative citing support among stakeholders for a mine restart.
While cautioning that the process could take longer, the representative said it was realistic that the government could announce a decision to proceed this year.
Potential contributors to organic growth Beyond Cobre Panama, Franco-Nevada identified several assets that could be meaningful growth drivers. The company cited Glencore’s Antapaccay operation in Peru, where the Coroccohuayco deposit is nearly the size of Antapaccay and has a higher grade, according to the representative. Glencore could sanction a construction decision for Coroccohuayco later this year or early next year, the representative said.
The company also highlighted the Candelaria copper-gold operation in Chile, where underground expansion work is underway and studies are evaluating a deeper open-pit pushback. The representative said additional deposits on the concession, including La Española and Portuguesa, could support a longer operating life.
On the royalty side, Franco-Nevada pointed to Agnico Eagle Mines’ Detour asset in Canada. The representative said Detour’s resource has grown to more than 40 million ounces and the mine has a plan to reach 1 million ounces of annual production, with potential for further growth from underground development. The company also cited the Côté project, where the Gosselin discovery has added another roughly 10 million ounces to the original Côté deposit, potentially supporting a larger mill expansion.
Exploration and financial-backer investments Franco-Nevada also discussed smaller royalties that it believes have significant potential, including Banyan Gold’s AurMac project in Yukon, Strickland Metals’ Rogozna project in Serbia and Tiernan Gold’s Volcan project in Chile. The company said each asset either has or could reach approximately 10 million ounces of resources.
The company said its strategy of supporting development teams has generated strong results. It cited G Mining Ventures and Discovery Silver as examples, stating that both companies’ stocks have increased tenfold since Franco-Nevada’s investments. Looking ahead, it said G Mining’s Tocantinzinho project is operating and showing exploration potential, while Discovery’s Porcupine assets in Timmins could benefit from the purchase of Glencore’s Kidd Creek mill, which may free capacity at the Dome mill for future processing of the Dome open-pit resource.
About Franco-Nevada (NYSE:FNV)Franco-Nevada Corporation NYSE: FNV is a gold-focused royalty and streaming company. Rather than operating mines directly, it provides capital to mining and natural resource companies in exchange for the right to receive a portion of future production or revenue. This business model gives Franco-Nevada exposure to commodity production while generally limiting its direct responsibility for operating and capital costs.
The company holds a diversified portfolio of royalties, streams and other interests tied primarily to gold, as well as silver, platinum-group metals, iron ore and other minerals.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Franco-Nevada Right Now?Before you consider Franco-Nevada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Franco-Nevada wasn't on the list.
While Franco-Nevada currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
SpaceX poprvé dostal Starship na oběžnou dráhu a vypustil 26 satelitů V3 Starlink, i když misi ukončila porucha motoru. Pro Rocket Lab to zvyšuje tlak na růst launchového byznysu, hlavně kvůli Neutronu, který ještě neletěl.
SpaceX (SPCX +1.08%) finally got Starship into orbit. On Monday, Sept. 28, the huge rocket's upper stage reached orbit for the first time and released 26 of the company's next-generation V3 Starlink satellites. An engine issue ended the mission early.
This might look like bad news for Rocket Lab (RKLB -0.03%). The space company is spending a lot on Neutron, a reusable rocket designed to compete for the sort of launch work SpaceX's Falcon 9 does now. And shares of the growth stock trade near $70 as I write, under half the 52-week high of $151.
Does a working Starship threaten Rocket Lab? I think it does, but mainly through Neutron, which hasn't flown yet.
Image source: Getty Images.
Starship's first customer is SpaceXA full Starship load of V3 satellites is designed to add as much capacity to Starlink as around 20 Falcon 9 flights of the smaller satellites SpaceX launches now. The flight carried 26 of the up to 60 V3 satellites SpaceX eventually plans to fly on every mission.
Most of SpaceX's launches already go to Starlink. The company flew 78 launches in the first half of 2026, and 61 of those were internal launches, mainly for Starlink. Just 17 were customer launches, down from 21 in the first half of 2025.
Put simply, Starship's job for now is building out SpaceX's own network.
Today's Change
(
1.08
%) $
1.62
Current Price
$
150.86
Launch is the smaller half of Rocket LabRocket Lab is a satellite company as much as a rocket company.
Launch services brought in around $108 million of its $434 million in first-half revenue, or about 25% -- a falling share, down from about 33% for all of 2025. Space systems (spacecraft, satellite components, and related services) made up the rest. That business grew 76% from the first half of 2025, helped by acquisitions, much faster than launch revenue's 32% rise. And around $1.4 billion of the company's $2.36 billion backlog at the end of June was linked to space systems.
Most of that doesn't rely on beating SpaceX to a launch contract.
The launch backlog, though, is growing faster. It almost doubled over six months: around $476 million when 2025 ended, $921 million by March 31, and $940 million by June 30. Launch now makes up 40% of the total backlog, up from about 26% at the start of the year.
Most of the rise was in the first quarter, when Rocket Lab signed five new dedicated Neutron launches and said it sold more launches than in all of 2025.
Rocket Lab doesn't say how much of the backlog is tied to Neutron. But some of the launch growth investors are banking on rides on a rocket that hasn't flown.
Premium Feature
Moneyball Superscore
81/100
Today's Change
(
-0.03
%) $
-0.02
Current Price
$
69.68
Where could Starship hurt?Neutron is a medium-lift rocket built to carry around 13,000 kilograms to low Earth orbit in its reusable version. Rocket Lab says it's tailored for commercial and U.S. government constellation launches. That pits it against Falcon 9 much more than Starship.
Some of Neutron's demand also comes bundled with spacecraft Rocket Lab makes itself. The U.S. Space Force awarded the company a $397 million contract (including options) to build Flatellite spacecraft that will launch on Neutron. A customer buying the satellites and the ride together is arguably tougher for a rival rocket to lure away.
I think the bigger risk is indirect. If Starship takes over Starlink deployment, Falcon 9 flights now used for SpaceX's own satellites might free up for paying customers -- the same constellation operators Neutron is after. More available Falcon 9 capacity may pressure launch prices right as Neutron tries to break in.
Of course, Starship isn't flying Starlink on a regular schedule yet, and SpaceX is still working toward the full and rapid reusability it's relying on to lower launch costs.
But Neutron isn't in the market yet, either. Rocket Lab said in August that it still aims to deliver the rocket to its pad in the fourth quarter, though the chance of a first launch before the end of 2026 is fading.
Still, is Starship a threat to Rocket Lab stock? I'd say yes, even though it hardly affects the space systems business that pays most of Rocket Lab's bills today. The pressure falls on launch growth, and launch growth is a big part of what investors are paying for in the stock's valuation.
At around $70 a share, Rocket Lab trades at over 40 times its annualized revenue. Its free cash flow was also negative by about $188 million in the first half. Plus, the company's next growth engine might face a cheaper, more available Falcon 9 by the time it flies. I think the stock's too pricey to own through that uncertainty.
Michael Micciche - Senior Vice President of Investor Relations
Yogesh Gupta - CEO, President & Director
Anthony Folger - Executive VP, CFO & Treasurer
Conference Call Participants
Lawrence Vensko - Guggenheim Securities, LLC, Research Division
Fatima Boolani - Citigroup Inc., Research Division
Lucky Schreiner - D.A. Davidson & Co., Research Division
John DiFucci - Guggenheim Securities, LLC, Research Division
Presentation
Operator
Hello, and welcome to Progress Software's Third Quarter Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Michael Micciche, SVP of Investor Relations. You may begin.
Michael Micciche
Senior Vice President of Investor Relations
Thank you, Tawanda. It's nice to have you back with us. Good afternoon, everyone, and thanks for joining us for Progress Software's Third Fiscal Quarter 2026 Financial Results Conference Call. Joining me on the call are Yogesh Gupta, our President and CEO, and Anthony Folger, our Chief Financial Officer. Before we get started, please consider our Safe Harbor statement. During this call, we will discuss our outlook for future financial and operating performance, corporate strategy, product plans, cost initiatives, our acquisition and integration of Domo, and other information that might be considered forward-looking.
Such forward-looking information represents Progress Software's outlook and guidance only as of today and is subject to risks and uncertainties, and our actual results may differ materially. For a description of the factors that may affect our future results and operations, please refer to the risk factors in our SEC filings, particularly the risk factor section in our most recent Form 10-K and the latest 10-Q filing, which was filed in conjunction with this announcement.
Progress assumes no obligation to update forward-looking statements included in this call. Additionally, please note that all the financial figures
Hunter Biden tvrdí, že jeho memecoin LAPTOP má „opačnou tokenomiku“ než Trumpovy memecoiny: insiderům připadá 30 % nabídky a polovina jde komunitě. Zároveň říká, že zakladatelské tokeny se nepohnuly a z fondu neodešel žádný dolar do kapes insiderů.
Biden said on Unchained that he designed LAPTOP as a contrast to the TRUMP memecoin and told critics who call it a scam to “look at the blockchain.”
Hunter Biden: LAPTOP has opposite tokenomics of Trump's memecoin
Posted September 30, 2026 at 10:21 pm ET.
Hunter Biden said he built his LAPTOP memecoin with the “opposite tokenomics” of the Trump family’s memecoins “to show that you can do this the right way.” He said insiders get 30% of LAPTOP’s supply, compared with what he described as 80% for the Trump tokens, and that half goes to the community.
“Look at the blockchain. All you have to do to see if it was a scam on my part is look,” Biden said on the Unchained Podcast on Wednesday.
The founder tokens “have never moved and are not going to move,” he added, and “not a single dollar has come out of the foundation into the pockets of any of the insiders.” The only insiders, according to Biden, are himself and two other Americans.
Get Unchained’s crypto news in your inbox with the free Unchained Daily newsletter.
The Founder Allocation Two Base wallets were each funded with 300 million LAPTOP before launch, according to Base blockchain data reviewed by Unchained.
That matches two allocations in the project’s disclosures: the founders’ share and a predictions pool whose tokens are burned when certain real-world predictions come true. Unchained could not confirm which wallet holds which allocation or who controls them. One has not moved any tokens.
The other has sent 17.5 million tokens, or 1.75% of supply, to a burn address. Founder tokens are locked for six months after launch and then vest monthly over 24 months, according to the disclosures.
The Launch-Day Spike LAPTOP fell more than 99% from its Sept. 9 launch-day peak on Base, as Unchained reported. The token traded near $0.079 on Wednesday, above its planned $0.05 launch price.
Biden said one of the token’s three market makers, which he could not name because of confidentiality, but which are named in the website’s disclosures as G20, GSR and Wintermute, made “a major error” by seeding the launch pool with about 29,000 tokens instead of 5 million. In his account, the token jumped from a $50 million fully diluted valuation to a $317 billion market cap within a minute. He called that figure “pure fiction” and said the firm has since admitted the mistake internally.
Biden took responsibility for the launch “regardless of whether it was a market maker’s fault or not.” What he should have done, he said, is explain LAPTOP more before launch, so skeptics would know it did not begin with someone asking him, “Hey, can we slap your name on something and see what happens?”
Instead, by his account, he spent “an enormous amount of time” trying to “learn the community, but also learn the technology.”
Related Listen: The Chopping Block: FOMO’s Co-Founder Defends the Memecoin Trenches, Hunter Biden’s $LAPTOP, and AMC vs Robinhood
AI-assisted content: This article was produced with the assistance of AI tools and was reviewed, edited, and fact-checked by a member of the Unchained editorial team before publication.
Tokenizovaná akciová platforma Ondo Finance dosáhla rekordního TVL 1,26 miliardy dolarů. Ondo Stocks tak překonala předchozí milník 1,01 miliardy dolarů.
Ondo Finance’s tokenized stock platform just set a new high. Total value locked on Ondo Stocks reached a record $1.26 billion.
How Ondo Stocks got to $1.26 billion Ondo Stocks launched in September 2025. It first pushed past the billion-dollar line on or around August 15, 2026, posting a TVL of $1.01 billion.
It didn’t stop there. The platform later climbed to its record $1.26 billion, a gain of roughly a quarter billion dollars on top of that first milestone.
What goes into that pile here is tokenized exposure to US stocks and ETFs. Ondo offers total-return exposure, so holders track both price moves and the returns that come with owning the underlying asset.
The product is aimed at retail and institutional users outside the US. Americans are not the target customer, at least for now.
Advertisement
The tokens also live on several networks. As of August 2026, Ondo Stocks supported a range of assets across Solana, Ethereum, and BNB Chain.
Ondo Global Markets, the business behind Ondo Stocks, ranks among the largest tokenized equity platforms by TVL.
Tokenized stocks are doing more than sitting still Ondo’s tokens have found their way into leveraged trading. They are also being posted as collateral in lending markets, where users can borrow against them.
Cumulative trading volume for the tokenized equities has exceeded several billion dollars, well above the platform’s current TVL.
The regulatory backdrop shifted In September 2026, the SEC issued a five-year innovation exemption covering on-chain trading of certain tokenized national market system stocks. NMS stocks are, broadly, the shares listed on major US exchanges.
The exemption is set to open the door to round-the-clock, 24/7 on-chain trading of select tokenized NMS stocks.
What this means for Ondo and tokenized equities A tokenized equity platform crossing $1 billion in under a year suggests demand is real rather than theoretical.
Ondo executives project TVL could reach $5 billion by the end of 2026. They point to improving regulatory clarity and growing interest from users who want direct, low-friction access to global stock markets.
For now, Ondo has a clean scoreboard to point at: launch in September 2025, $1.01 billion in mid-August 2026, and a record $1.26 billion after that.
Disclosure: This article was edited by Kaye Quema. For more information on how we create and review content, see our Editorial Policy.
LayerZero posílil díky novým institucionálním integracím pro regulované stablecoiny, včetně USAT od Tether a KRW1 v Koreji. ZRO za 24 hodin vzrostl o 16,46 % a míří k hranici $2, ale RSI na 78,05 varuje před krátkodobou korekcí.
LayerZero’s [ZRO] regulated stablecoin push was reinforced as new institutional integrations broadened its role across dollar- and won-denominated assets.
Specifically, Anchorage Digital reportedly selected LayerZero as an interoperability collaborator for Tether’s USAT stablecoin. The asset utilizes the Omnichain Fungible Token standard associated with LayerZero.
The framework enables USAT to function natively across the supported blockchains rather than depending on the wrapped versions.
Additionally, LayerZero’s stablecoin infrastructure also extended beyond the U.S. market through a different partnership with BDACS, a Korean digital asset custodian.
In particular, the digital asset management firm recently picked LayerZero technology for KRW1, its Korean won-backed stablecoin.
Both the integrations combined expanded LayerZero’s infrastructure across the regulated stablecoin initiatives, hence targeting different currencies and markets.
Spot buyers drive ZRO’s rally The above-mentioned institutional developments emerged alongside a robust activity across ZRO’s spot market.
Notably, ZRO price surged 16.46% over 24 hours at press time, while its spot trading volume expanded 22.24% within the same period.
Furthermore, the Spot Taker CVD indicator also printed taker-buy dominance, suggesting the bulls aggressively controlled the prevailing market orders over the measured period.
The activity introduced additional context behind the price rally as the advance coincided with the expanded spot participation. The token’s market capitalization climbed to nearly $677.98 million following the recent price expansion.
Besides, its unlocked market capitalization stood higher at roughly $1.28 billion, suggesting the broader valuation of the circulating unlocked supply.
Source: ZRO Spot Taker CVD on CryptoQuant OI rises as Futures volume cools As ZRO price pushed higher, the derivatives activity, on the other hand, presented a more mixed outlook.
At the time of writing, LayerZero’s Open Interest (OI) saw a surge of 13.73% to around $187 million, highlighting more outstanding derivatives positions entered the market during the price uptick.
The derivatives trading volume, however, fell 14.51% to $203.41 million during the measured 24-hour period. This divergence implied that the outstanding exposure increased even as overall derivatives turnover declined.
The recent price expansion in positioning, therefore, had not been accompanied by a similar increase in futures trading activity.
Source: ZRO Open Interest on CoinGlass ZRO eyes $2 as RSI overheats ZRO’s price action strengthened considerably following a recovery from the September lows around the $0.973 support region. The rally cleared the $1.526 resistance, converting a crucial resistance level into the next potential support area.
At the time of writing, ZRO market value traded around $1.85, placing the token within reach of the psychological $2 resistance region. The MACD indicator remained bullish, with the MACD line extending above its signal line as the positive histogram bars persisted.
The technical indicator favored continued upside pressure as the bulls defended the breakout above the $1.526 region. Notably, the RSI climbed to 78.05, placing ZRO firmly within the overbought conditions and increasing a possibility of a short-term correction following the rapid advance.
Ultimately, a price correction could retest the $1.526 support level before another upside attempt in case the bulls continue defending the breakout.
Source: ZRO/USDT Daily Chart on TradingView Final Summary LayerZero’s regulated stablecoin integrations strengthen ZRO’s narrative as spot demand increases. ZRO could test $2, although an overbought RSI raises short-term pullback risks.
Bitcoin Policy Institute zpochybnil navrhované změny pravidel MSCI, které by mohly vyřadit některé bitcoinové treasury firmy z indexů spravujících asi 21 bilionů USD. Uvedl, že by to mohlo zasáhnout i Strategy a Metaplanet.
PANews reported on October 1 that the Bitcoin Policy Institute released a report titled "Wall Street's Invisible Committee," questioning MSCI's proposed changes to index inclusion rules that could exclude certain Bitcoin treasury companies (Digital Asset Treasury Companies, DATCOs). The institute stated that MSCI-managed indices involve roughly $21 trillion in benchmark assets, and when index rules change, funds tracking the relevant indices may need to adjust their holdings, triggering large-scale capital reallocation.
The Bitcoin Policy Institute said that MSCI had previously proposed in 2025 to exclude digital asset treasury companies (i.e., enterprises with at least 50% of assets in digital assets), but suspended the move after encountering opposition. This year, MSCI reintroduced a broader classification standard targeting "non-operating companies," and simulations showed that the rule could exclude companies such as Strategy and Metaplanet. The institute found an internal file path containing "Projects/DATCOs/Operating vs Non Operating" in the metadata of MSCI's public consultation documents, which it said raised questions about whether the rule was designed to target digital asset companies. However, the institute also acknowledged that metadata alone cannot prove that MSCI predetermined the exclusion outcome.
In addition, the Bitcoin Policy Institute noted that MSCI published an article titled "Creeping Crypto" in 2021 discussing the impact of crypto assets entering the stock market, and examined companies' crypto asset exposure from an ESG perspective. At the same time, the institute pointed out that MSCI's management has publicly supported ESG investment principles in the past.
The Bitcoin Policy Institute believes that the "operating assets" standard MSCI intends to adopt lacks a sufficiently clear classification framework and could affect companies in emerging industries, and called for greater transparency and reproducibility in the index-setting process. The report represents the views of the Bitcoin Policy Institute, and MSCI has not yet responded to the report.
Robinhood přidává americkým zákazníkům krypto perpetual futures s pákou až 10x na Bitcoin a Ether. Spuštění umožnily CFTC no-action letter, Bitstamp a Robinhood Derivatives.
Robinhood is bringing crypto perpetual futures to US customers, with up to 10x leverage on Bitcoin and Ether. Nicola White, Robinhood’s vice president of institutional crypto, explains how the CFTC no-action letter, the Bitstamp exchange, and Robinhood Derivatives made it happen, and why the company wants markets to be always on.
Chapters:
0:00 Robinhood’s Hood Summit: 24/7 Stock Trading and US Crypto Perps
0:40 Why Robinhood Wants Markets That Never Close
1:32 Bitstamp Perps and the CFTC No-Action Letter
2:19 Tokenized Stocks, the Basis Trade, and the Path for US Perps
3:20 Bitstamp’s Volume and the Retail–Institutional Merger
4:54 What Institutions Want to Do With Bitcoin
6:00 Institutional Bitcoin Depth and Large Block Trades
6:49 AI Trading Agents and Robinhood’s Sub-Account Controls
8:29 Lessons From the 2022 Meltdown and US Leverage Limits
10:12 How Bitcoin Changes Finance in 10 Years and What’s Next for Tokenized Stocks
DISCLAIMER: The views and opinions expressed in this show are those of the participants and do not necessarily reflect the official policy or position of BTC Inc., Bitcoin Magazine, or any affiliated entities. This content is provided for informational and educational purposes only and should not be construed as investment, legal, tax, or accounting advice. Nothing contained in this show constitutes a solicitation, recommendation, endorsement, or offer to buy or sell any securities or financial instruments. Viewers should consult their own advisors before making financial or business decisions.
Patrick Green
Patrick Green is an Assistant Producer and Channel Manager on the multimedia team at Bitcoin Magazine, focusing on production, content distribution, and channel strategy across the network.
Coinbase získala schválení od CFTC pro spuštění vlastního amerického clearingového centra pro kryptoderiváty. Analytici to spojují s potenciálem pro XRP a cílem 10 USD.
Coinbase has secured approval from the Commodity Futures Trading Commission (CFTC) to launch its own US-based crypto derivatives clearinghouse, a development that could have significant implications for XRP within the regulated derivatives market.
XRP’s integration with Coinbase derivativesXRP is already traded on Coinbase’s derivatives platform, underscoring its established presence within the exchange’s trading ecosystem. Market observers note that Coinbase focuses its infrastructure efforts around assets that are actively supported, not marginalized. This move signifies that XRP is situated within a market Coinbase views as important for the future of regulated crypto trading.
Crypto analyst Levi Rietveld from Crypto Crusaders emphasized the importance of regulated infrastructure, stating that the development is not about short-term price speculation, but rather an expansion of robust market foundations. Rietveld noted, “This isn’t about guessing where XRP’s price goes next; it’s about Coinbase expanding the regulated infrastructure around a market where XRP is already traded.”
This development centers on Coinbase increasing regulated infrastructure in markets where XRP is already present, which analysts say could make the asset more accessible to institutional participants.
The focus remains on infrastructure and compliance, moving beyond volatile sentiment to highlight the environment in which XRP now operates.
Institutional adoption through regulatory clarityInstitutional investors often require regulatory certainty before allocating significant capital to crypto markets. The establishment of Coinbase Clearing LLC as a CFTC-registered derivatives clearing organization addresses this need, supporting fully collateralized instruments such as futures, options on futures, and swaps, with USDC as collateral and 24/7 settlement available for participants.
Coinbase, a leading American cryptocurrency exchange, now controls all key components of a regulated derivatives infrastructure: a futures commission merchant, a derivatives exchange, and a clearinghouse. This comprehensive structure is expected to provide the support and confidence institutions look for when considering large-scale entry into digital assets.
Rietveld explained that if institutional investment in crypto continues to rise, regulated infrastructure such as this gives XRP an advantage as it is already included on Coinbase’s derivatives platforms.
Mini dictionary: CFTC-registered derivatives clearing organization, an entity approved by the CFTC to clear and settle derivatives trades in compliance with US regulations, offering transparency and security for institutional and retail participants.
$10 price projection linked to infrastructure developmentRietveld connected the regulatory advancement directly to a potential XRP price target of $10 and higher, suggesting that the growth of regulated infrastructure is critical for unlocking institutional participation at scale. He argued that significant financial flows are likely to move through venues with strong compliance frameworks, which could boost demand and liquidity for XRP moving forward.
He further indicated that as Coinbase’s regulated clearinghouse expands and supports XRP, it could facilitate access for institutional traders, who are typically required to operate within regulated environments.
Access to regulated clearing venues could be the catalyst that increases institutional demand for XRP, a trend that some analysts believe is essential for major price appreciation.
The projection draws a direct line from regulatory clarity and market infrastructure to potential price milestones, highlighting the role of institutional engagement in driving expansion.
Broader market impactCoinbase’s approval marks one step in a larger shift toward more regulated frameworks within US crypto markets. This trend, characterized by clear regulatory oversight and expanded access to compliant derivatives, is seen as a catalyst for higher trading volumes and potentially greater price discovery.
XRP’s position within this environment is notable, as regulated infrastructure developments support larger market participation and may differentiate XRP from assets lacking similar integration. Rietveld and other analysts point out that the long-term significance of these developments may outweigh short-term speculation on price movements.
RippleX otevřel hlasování validátorů o aktualizaci LendingProtocolV1_1 pro XRPL. Aktivace ale vyžaduje i schválení původních návrhů LendingProtocol a SingleAssetVault.
The XRP Ledger has now inched closer to launching its long-awaited native lending infrastructure. The new LendingProtocolV1_1 amendment is now open for validator voting.
RippleX announced on Sept. 30 that validators can now evaluate and vote on LendingProtocolV1_1.
The upgrade comes with two significant changes to the XRPL lending architecture: closed-ended lending vaults and cash-basis accounting.
HOT Stories
The amendment extends two other proposed pieces of XRPL infrastructure (LendingProtocol and SingleAssetVault).
According to RippleX, LendingProtocolV1_1 must activate alongside the original LendingProtocol and SingleAssetVault amendments.
The amendment changes how that pooled capital can be used for lending.
You Might Also Like
It was included in XRP Ledger server version 3.4.0, released on Sept. 16. The release formally introduced LendingProtocolV1_1 to 'xrpld.'
Opening validator voting is not the same as activation.
A proposed change must receive support from more than 80% of trusted validators. Furthermore, it must maintain that level of support for two weeks. If support falls back to 80% or below during that period, the two-week countdown resets.
Closed-ended vaultsLendingProtocolV1_1 has introduced the ability to create a second type of Single Asset Vault.
Single Asset Vaults pool one type of asset from multiple depositors and make that capital available to another protocol. A vault can hold XRP, a trust line-issued token or a Multi-Purpose Token.
An open-ended vault works like an investment pool that remains continuously accessible. Users can deposit capital and receive shares based on the prevailing price per share.
Approving V1_1 alone would not suddenly create a functioning XRPL lending market.
RippleX says all three amendments (SingleAssetVault, LendingProtocol and LendingProtocolV1_1) are required for operational lending.
The Sept. 30 vote should be viewed as a procedural milestone.
Aerodrome Finance a Velodrome Finance se sloučí do platformy Aero, která má rozšířit adresovatelný trh z 7 miliard USD na více než 63 miliard USD TVL. Integrace má být spuštěna v říjnu 2026.
Two of DeFi’s better-known liquidity hubs are becoming one. Aerodrome Finance and Velodrome Finance are merging into a single platform called Aero, and the pitch is all about reach.
According to the announcement, Aero will grow its addressable market from $7 billion to over $63 billion in total value locked. It will also serve chains that together handle $135 billion in monthly trading volume.
What the merger actually involves The consolidation was announced in mid-November 2025. The integration is set to go live in October 2026.
The end product is meant to be simple on the surface. Users get one token and one interface instead of two of each.
Advertisement
Under the hood, Aero merges the existing ve(3,3)-style tokenomics that both Aerodrome and Velodrome run on. Holders lock up tokens for a period of time, receive voting power in return, and use that power to steer where new token rewards flow. Combining two of these systems into one means a single set of voters directing incentives across a much bigger map.
The unified protocol is planned to operate across chains including Base, Optimism, and Ethereum mainnet.
What happens to VELO holders For anyone holding VELO, the key question is the swap. VELO holders are expected to convert into AERO at a defined ratio, with one proposed ratio set at 0.55:1. Put simply, under that proposal each VELO would become 0.55 AERO. The word doing the heavy lifting there is “proposed,” so holders should treat the figure as a draft rather than a signed contract.
Why fragmentation is the real target The stated goal of the merger is to cut down on the inefficiencies created by fragmentation in Layer-2 ecosystems. Layer-2 networks are separate chains built on top of Ethereum to make transactions cheaper and faster. The catch is that each one tends to develop its own pool of liquidity. Money sitting on one chain does not automatically help a trader on another.
Aero is positioning itself as a single liquidity layer for Ethereum-aligned chains instead of a scattered collection of smaller pools.
What this means for traders and the DEX landscape For liquidity providers, the draw is scale. A protocol that can tap into chains carrying $135 billion in monthly volume offers far more fee-generating opportunities than one confined to a narrower footprint.
That assumption matters. Serving chains with $135 billion in monthly trading volume is not the same as processing $135 billion in monthly trading volume. The figure describes the size of the pond, not the size of the catch.
The same logic applies to the $63 billion number. It reflects the total value locked across the markets Aero intends to serve, not deposits Aero already holds.
For AERO and VELO holders, the practical items to watch are clear. Keep an eye on whether the conversion ratio is finalized as proposed, how the merged ve(3,3) voting system is structured, and how quickly liquidity actually shows up on new chains once Aero goes live in October 2026.
Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.
Lido uvedlo, že MetaMask Staking po bezpečnostním incidentu začne v protokolu ukončovat své validátory Ethereum. Dokončení procesu očekává nejpozději do 7. října 2026.
PANews reported on October 1 that Lido stated on X that, following an investigation into an infrastructure breach, MetaMask Staking (formerly known as Consensys Staking) has taken precautionary measures to protect client assets related to the Ethereum validator nodes it operates.
Lido said these measures include exiting the Ethereum (ETH) validator nodes it operates within the Lido protocol. The related operations may result in forgoing some staking rewards, and may incur downtime penalties due to future validator node shutdowns aimed at reducing potential network slashing risks. At present, the relevant validator nodes have begun the exit process, which is expected to be completed by October 7, 2026 at the latest (though not all withdrawals have been completed yet).
Lido stated that stETH holders do not need to take any action. The ETH exited from MetaMask Staking's operated validator nodes is expected to gradually return to the protocol after the relevant validator nodes complete their exit, withdrawal, and re-entry into the staking cycle. Due to the current long Ethereum validator entry queue, the entire process is expected to take up to approximately 45 days. Staking is inherently a non-custodial model, and MetaMask will not manage staking withdrawal keys on behalf of clients.
In addition, Lido's diversified node operator system, along with security mechanisms including an ad hoc reserve fund of more than 6,750 stETH, is designed to control and mitigate the impact on the protocol's normal operations.
Spotové Dogecoin ETF v USA zaznamenaly v září čistý příliv 3,71 mil. USD, což je jejich druhý nejlepší měsíční výkon od spuštění. Grayscale GDOG táhne většinu přílivů, zatímco Bitwise plánuje BWOW ukončit.
September Shapes Up as a Banner Month for $DOGE ETFsSpot Dogecoin ($DOGE) ETFs are closing out September 2026 in strong form. The three U.S.-listed funds have collected $3.71 million in net inflows during the month, putting them on course for their second-best monthly performance since launch, according to @BSCNews.
CoinGape reported that the $3.71 million in September inflows represent the highest monthly figure posted by these ETFs since January 2026, when the funds pulled in $4.07 million during their debut month. The data also shows that the funds have now recorded three consecutive weeks of positive flows, a streak that underscores a clear shift in sentiment toward the asset.
The bulk of the recent inflows have been concentrated in Grayscale's GDOG. KuCoin News noted that cumulative inflows into GDOG rose to $15.46 million following a record week ending September 25, when the combined funds drew $2.89 million, their strongest weekly figure since launch per SoSoValue data.
Bitwise Exit and the Broader Market ContextThe picture is not entirely straightforward. Bitwise announced on September 10 that it would liquidate its DOGE ETF, BWOW, with final trading set for October 14. After that date, only two U.S. spot Dogecoin funds will remain active. Some of the recent inflow momentum into Grayscale's GDOG may partly reflect capital rotating out of the Bitwise product ahead of its closure.
The broader $DOGE market has also seen renewed life. Dogecoin gained roughly 13% in September 2026, coinciding with the uptick in ETF flows. The U.S. spot Dogecoin ETF market itself is still relatively young. 21Shares launched TDOG on Nasdaq on January 22, 2026, the first SEC-approved spot Dogecoin ETF, physically backed on a 1:1 basis and carrying a 0.50% management fee.
With total ETF assets still representing a fraction of Dogecoin's overall market cap, the scale of institutional interest remains modest in absolute terms. However, three straight weeks of inflows and a near-record monthly total suggest that appetite is building heading into the final quarter of 2026. Whether this marks the start of a sustained memecoin season or simply a short-term uptick in risk appetite remains to be seen.
SourcesCoinGape: Dogecoin Price Prediction, Whales Remain Bullish Amid 3-Week DOGE ETF Inflow Streak
KuCoin News: Dogecoin ETFs See Record $2.89M Inflows Amid Bitwise Exit
GlobeNewswire: 21Shares Announces Launch of the 21Shares Dogecoin ETF (TDOG)
Open Food Chain na Cardanu ukotvuje ověřená data o dodavatelském řetězci a zpřístupňuje je zákazníkům přes QR kód na obalu. První test u Chocolatemakers ukázal, že kód naskenovala desetina nakupujících, kteří po naskenování strávili v průměru 42 sekund.
Open Food Chain, a consortium partner of the Cardano Foundation (@Cardano_CF), is anchoring verified supply chain data on @Cardano and surfacing it to shoppers through a QR code printed on product packaging. Scan the code, and a consumer can trace a deforestation-free claim all the way back to the source farm. No token changes hands anywhere in the process.
From Compliance Cost to Competitive Advantage The pitch is straightforward: brands already pay for audits, certificates, and supplier evidence. Open Food Chain takes that existing documentation and converts it into a scannable digital product passport, anchored on Cardano so the underlying data cannot be quietly altered after the fact. According to Open Food Chain, the platform turns traceability records, certificates, and supplier evidence into a live passport accessible through a single QR code, with each claim linked to its evidence, scope, and review status.
Kraft Heinz and dairy trader Interfood are among the early enterprise partners. On the Kraft Heinz side, the collaboration is designed to deploy enterprise-grade food traceability on @Cardano, enabling transparent and scalable data flows across global food value chains, according to a Project Catalyst proposal outlining the initiative. Open Food Chain is contributing co-funding alongside Kraft Heinz technical staff for integration and validation workflows.
Early In-Store Numbers Show Consumer Pull The first real-world retail test ran on Chocolatemakers chocolate. One in ten shoppers scanned the QR code, and those who did spent an average of 42 seconds engaging with the product story behind it. For a shelf interaction, that is a meaningful dwell time and early evidence that transparency, when made accessible, can influence purchasing behavior.
The broader context matters here. European regulators are tightening rules around deforestation and green claims, putting pressure on food brands to back up sustainability statements with verifiable evidence. Open Food Chain is positioning Cardano as the record-keeping layer that makes those claims tamper-evident and auditable, without requiring the consumer to know anything about blockchain. The QR code is the only interface they need.
Open Food Chain, founded in 2017 and based in Amsterdam, has built out deployments across cacao, juice, and meat value chains, with the platform used by more than 3,000 farmers, cooperatives, processors, and retailers across multiple continents, according to the Project Catalyst proposal. Its architecture has been redesigned to consolidate previously separate industry-specific chains onto a single platform integrated with @Cardano.
Sources:
Open Food Chain: Official Website
Project Catalyst: Kraft Heinz Scaling Enterprise Food Traceability on Cardano
Senátní vyšetřování uvádí, že Írán využívá USDT od Tetheru k obcházení sankcí a financování proxy skupin včetně Hizballáhu. Z 846 sankcionovaných peněženek obchodovalo 84 % téměř výhradně v USDT.
Iran has been leaning on Tether’s dollar-pegged USDT to dodge a U.S. sanctions dragnet and move money for the regime and proxies such as Hezbollah, according to a new Senate Democrats report.
The Permanent Subcommittee on Investigations says the token has become a primary payment rail for Tehran and a funding tool for terrorist proxy groups, reports The Wall Street Journal, which viewed a copy of the findings.
Tether’s USDT accounts for about 60% of all stablecoins by market capitalization. Because the token tracks the dollar, it is less volatile than other crypto — making it useful for payments and, the Journal notes, for money laundering.
Treasury has been tightening the economic squeeze since U.S. military strikes in Iran earlier this year, including August’s Operation Economic Outcast.
Sen. Richard Blumenthal (D-Conn.) led the probe, which reviewed 846 wallets sanctioned by the U.S. and Israeli governments over Iran ties and found that 84% of them traded exclusively or almost exclusively in USDT.
Blumenthal told the Journal the report “exposes how Tether and its flagship token have become central to Iran’s shadow banking system, allowing the Iranian government to fund its regional proxies, commit human-rights abuses, and pursue hostile drone and missile programs as they defy our sanctions regime.”
A Tether spokesman did not return requests for comment. The company has worked with law enforcement to freeze some regime-linked wallets.
Iran may be easing off: TRM Labs data shows USDT’s share of volume in Iran-attributed wallets fell from 72% in 2024 to 67% in 2025, and to 14% of on-chain volume in August.
Brookfield Renewable rozšiřuje kapacity v oblasti obnovitelných zdrojů, úložišť a jaderné energetiky kvůli rostoucí poptávce po elektřině ze strany datových center a AI. Firma má přes 5 GW provozních úložišť a pipeline přes 30 GW.
Bloom Energy's Game-Changing AI Deal: Why the Rally Has LegsBrookfield Renewable Partners NYSE: BEP outlined plans to expand its renewable power, energy storage and nuclear businesses as executives cited rising electricity demand, grid constraints and growing needs from data centers and artificial intelligence.
Chief Executive Officer Connor Teskey said the energy market is entering an era in which demand “significantly outweighs supply,” driven by electrification, industrial reshoring and energy-intensive AI and data-center growth. He said the company expects renewables, batteries and nuclear power to capture a substantial portion of new energy demand because of their respective cost, flexibility and baseload-power characteristics.
Get BEP alerts:
Focus on renewables, storage and nuclear 3 Renewable Energy Stocks That Could Gush as Oil Stays VolatileTeskey said Brookfield Renewable has operating platforms in 35 countries and is nearing a run rate of commissioning 10 gigawatts of new projects annually. The company has continued to expand its renewables operations through investments including Boralex and Isagen, while identifying opportunities to use existing grid connections and development sites for data-center-related powered-land projects.
The company also highlighted its hydroelectric portfolio, which Teskey said is the largest in North America. While hydro additions are limited, he said the existing fleet is being recontracted at higher prices, supporting cash-flow growth.
The 6 Best Energy Stocks to Buy NowEnergy storage is becoming the company’s fastest-growing segment, according to Teskey. Brookfield Renewable has built its storage operations through the 2024 acquisition of Neoen, focused on Europe and Australia, and the 2026 acquisition of Aypa, focused on North America. Teskey said the company has more than 5 GW of operating storage assets and an advanced pipeline exceeding 30 GW.
Managing Director of Investments Amanda Laszutko said the company had virtually no battery-storage capacity three years ago but now has 5 GW of operating capacity and an 80-GW development pipeline. She said battery costs have fallen roughly 60% over the past 24 months, while contracting structures have evolved to support long-term investment.
Laszutko cited a recently signed 15-year solar-plus-storage power purchase agreement in Australia with a large hyperscale customer. The 140-megawatt project was described as one of the customer’s first combined solar-and-storage PPAs in the country.
Brookfield Renewable also emphasized its exposure to nuclear power through Westinghouse. Teskey said Westinghouse services more than 60% of operating nuclear reactors globally and has technology for new nuclear construction. He said the company is pursuing nuclear-build opportunities in Europe, the Middle East and Asia, while Westinghouse has signed agreements with the U.S. government intended to support nuclear new-build activity.
Development and acquisition targets Laszutko said Brookfield Renewable expects to deliver approximately 11 GW of new capacity annually beginning in 2028, nearly 40% above the capacity delivered over the previous 12 months. The company said it has a 90-GW advanced pipeline across solar, storage and wind projects.
Development has grown from less than 1 GW annually in 2021 to 8 GW over the past 24 months, according to Laszutko. She said the company combines local teams in 35 power markets with global development, commercial and financing capabilities.
The company also plans to continue pursuing large-scale acquisitions. Laszutko said Brookfield Renewable closed four investments over the past two years with enterprise values of more than $6 billion each. Collectively, those investments represent 15 GW of operating capacity and a 50-GW pipeline across 16 countries, she said.
Brookfield Renewable raised its five-year capital-deployment target to more than $11 billion from $10 billion. Laszutko said planned deployment includes nuclear, baseload power, solar, wind, storage and technologies reaching commercial inflection points.
Cash flow, funding and capital recycling Chief Financial Officer Patrick Taylor said Brookfield Renewable reported record funds from operations per unit over the past 12 months and increased its distribution for the 15th consecutive year. He said the company raised $37 billion of financing in 2025 and expects financing raised in 2026 to exceed $40 billion.
Taylor said 90% of the company’s cash flows and generation are contracted for more than 12 years, while 70% of cash flows are inflation-linked. He also said more than 90% of cash generation comes from mature technologies and that 95% of financing is fixed-rate, with a 14-year term.
Without additional acquisitions, Taylor said the company expects to grow cash flows by more than 10%, supported by inflation-linked contracts, higher recontracting prices, operating-plan execution and development growth.
Capital recycling remains a central funding source. Taylor said Brookfield Renewable generated $1 billion of net proceeds from asset sales and capital recycling over the past 12 months and $4 billion over the past five years. The company expects to generate at least $1 billion annually from capital recycling going forward.
The company has also established two private renewable vehicles, Northview in North America and a European vehicle formed with Mitsubishi. Taylor said their seed portfolios total nearly $2 billion of equity, with frameworks to sell an additional $3.5 billion of equity over coming years.
Valuation catalysts Executives identified corporate simplification, nuclear expansion and further scaling of the funding model as potential catalysts for the company’s valuation. Taylor said the proposed simplification is intended to create a single consolidated security, potentially improving liquidity, index inclusion and passive-investor demand.
During the question-and-answer session, Teskey said the company remains focused on ensuring operating performance is reflected in its share price. He said Brookfield Renewable could repurchase shares or pursue initiatives such as corporate simplification, adding that management views the market’s assessment of higher interest rates as disconnected from the company’s inflation-linked revenues and ability to pass financing costs through to customers.
About Brookfield Renewable Partners (NYSE:BEP)Brookfield Renewable Partners L.P. is a renewable power and energy transition company that owns and operates a diversified portfolio of clean energy assets. Its main activities include generating electricity from hydroelectric, wind and solar facilities, as well as providing energy storage and other decarbonization solutions.
The company serves electricity markets and commercial, industrial and utility customers across North America, South America, Europe and the Asia-Pacific region. In addition to operating renewable power facilities, Brookfield Renewable develops new projects and invests in businesses supporting the transition to lower-carbon energy, including distributed energy and sustainable solutions.
Brookfield Renewable traces its origins to Brookfield Asset Management's renewable power operations and became publicly listed as Brookfield Renewable Energy Partners in 2011.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Brookfield Renewable Partners Right Now?Before you consider Brookfield Renewable Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brookfield Renewable Partners wasn't on the list.
While Brookfield Renewable Partners currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
AvengerDAO Security Marketplace na BNB Chain přidal šest nových bezpečnostních firem a rozšířil se na 17 firem. Platforma propojuje vývojáře přímo s prověřenými security firmami bez nutnosti předchozí žádosti.
BNB Chain’s security bench just got deeper. Six new security firms have joined the AvengerDAO Security Marketplace, lifting the total roster to 17.
From 11 to 17 in a matter of weeks The Security Marketplace launched on August 12, 2026, with an initial cohort of 11 carefully selected firms. By October 2026, that number had climbed to 17.
The marketplace is designed to connect developers building on BNB Chain with security firms that have already been screened.
One notable feature: projects can engage directly with the listed security firms. They do not need to submit a prior application first.
The marketplace also incorporates bug bounty support. Bug bounties pay outside researchers to find vulnerabilities before attackers do, essentially turning potential hackers into paid consultants.
The BNB-SS standard and how it fits in Alongside the marketplace, AvengerDAO has introduced the BNB-SS security standard. It is built around five pillars, which include governance and oracle integrations among other areas.
Governance covers how a protocol makes decisions and who holds the keys to change things. Oracles are the data feeds that bring outside information, like asset prices, onto the blockchain.
A security initiative with a longer history AvengerDAO itself is not new. It launched on September 20, 2022, as part of BNB Chain’s broader push to protect users against exploits and scams.
Early partners included CertiK, SlowMist, and PancakeSwap.
In 2025 alone, AvengerDAO’s risk APIs issued 38 million warnings.
The loss numbers tell the story The most striking data point is the trend in BNB Chain’s security losses. According to the research findings, losses fell 85% in 2023.
The declines kept coming. Losses dropped 69% in 2024 and 56% in 2025, marking three consecutive years of reductions.
What this means for builders and users For developers on BNB Chain, the expansion mainly means more choice. A pool of 17 vetted firms offers a better shot at finding an auditor with the right specialty, availability, and price point.
The no-application model also lowers the barrier for smaller teams.
The research findings frame the falling loss figures as a potential confidence boost for projects tied to AvengerDAO, and as a factor that could make BNB Chain-based projects more attractive to investors.
Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.
Open Standard jmenoval Chainlink oficiálním datovým orákulem pro stablecoin Open USD (OUSD). Integrace má od spuštění umožnit jeho použití v DeFi jako kolaterál, v likviditních poolech i jako margin pro perpetual futures kontrakty.
@openstandard has named @chainlink as the official data oracle for its Open USD stablecoin, a move that opens OUSD up to a broad range of decentralized finance applications on the day of its public launch.
Chainlink's price feeds will allow DeFi platforms to use OUSD as collateral for lending protocols, in liquidity pools, and as margin for perpetual futures contracts. Securing a reliable oracle from day one is a meaningful step for a new stablecoin looking to gain traction in DeFi markets, where accurate and tamper-resistant price data is a baseline requirement.
A heavyweight debut for OUSD Open USD went live on September 30, 2026, putting Open Standard's token directly into a market long ruled by Tether and Circle, but with a structure that spreads ownership far wider than either of its rivals. Open Standard's wider partner network has grown from over 140 to more than 200 companies, with UBS, SBI Holdings, and Jeeves among the newest additions.
Coinbase, Mastercard, Shopify, Stripe, and Visa have invested as the company's first five founding partners, each receiving an equal initial equity stake, and together the group has committed more than $1 billion to help establish OUSD liquidity over the coming months.
OUSD is being issued natively on Base, Ethereum, Solana, and Tempo. The token is issued by Bridge, the stablecoin infrastructure firm Stripe owns, with reserves held at BlackRock, Lead Bank, and BNY. Bridge will publish reserve attestations monthly.
Built for business, not just crypto markets Open Standard launched OUSD so that businesses everywhere can use stablecoins as easily as they use fiat. OUSD is purpose-built for use cases across banking, cross-border payments, settlement, institutional trading, and more.
The twist is in the economics: businesses can mint and redeem OUSD at par without fees or volume caps, while participating companies collect most of the income generated by the token's reserves. The stablecoin market OUSD is entering is worth over $300 billion, with Tether's USDT at roughly $143 billion and Circle's USDC at about $74 billion.
The Chainlink integration is designed to ensure OUSD can move fluidly through that DeFi landscape from the outset, rather than waiting for oracle support to be retrofitted after launch.
Sources:
Open Standard: OUSD is live (Official blog)
CoinDesk: New stablecoin Open USD goes live
Unchained: Open USD Stablecoin Goes Live
AI agents can now hire humans. The gig is to walk around the physical world and capture it in 3D, with payment in USDC settled on Circle’s Arc blockchain.
The use case is narrow but not trivial. Physical AI and robotics systems need accurate, current spatial data, and the most reliable way to get it is still to send a person with a camera.
How the agent-to-human pipeline works Arc is Circle’s Layer-1 blockchain. That means it is a base network with its own rules for processing transactions, not an add-on built on top of another chain. It officially launched on September 16, 2026.
Its defining design choice is that USDC does double duty. The dollar-pegged stablecoin serves as both the gas token, which pays transaction fees, and the settlement currency.
Most blockchains charge fees in a volatile native token. That makes budgeting awkward for an automated system paying out small amounts. On Arc, a dollar in fees stays a dollar, so an agent can price a job without betting on crypto markets.
One of the platforms built on this setup is VANGRID. It matches AI agents with human participants who produce 3D models of real-world locations.
The workflow looks like this:
An agent posts a request for a scan of a specific place. A human contractor captures the location. The finished model is delivered as a GLB file, a common format for 3D assets. Each scan carries cryptographic provenance and a timestamp, and it is tied to filtered location data. Payment runs through escrow. The agent’s USDC is held until the scan is accepted, and refunds are available if delivery fails.
Arc also supports agent-driven micropayments with sub-second transaction finality.
A small but growing marketplace category VANGRID is not the only example. RentAHuman is another marketplace emerging alongside Arc. It uses the network’s escrow features to handle a range of real-world tasks that agents send to people.
What this means for USDC, Circle, and physical AI For Circle, Arc is a bet that stablecoins can be infrastructure, not just a trading instrument. Using USDC as the gas token ties network activity directly to demand for the stablecoin itself.
There are open questions worth watching.
Quality control. Escrow releases funds when a scan is accepted. The key issue is who, or what, decides acceptance, and how disputes get resolved when an agent and a human disagree about whether a model is good enough.
Labor dynamics. A marketplace where software sets the terms and humans compete for tasks raises familiar gig-economy concerns about pay rates and bargaining power.
Privacy and location data. Scans tied to real places carry obvious sensitivities. The use of filtered location data suggests the platforms are aware of this.
Network concentration. Arc is Circle’s chain and USDC is Circle’s stablecoin. Builders gain a tightly integrated stack, but they also take on dependency on a single issuer for both fees and settlement.
Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.
Coinbase plánuje finanční účty pro AI systémy a autonomní agenty, navazující na agentic wallets a platební nástroje pro softwarové transakce. Firma už přes x402 zpracovala více než 100 milionů plateb, z více než 99 % v USDC.
Coinbase has unveiled plans to build financial accounts tailored for artificial intelligence (AI) systems and autonomous agents, aiming to expand its agentic finance initiative. CEO Brian Armstrong stated on X that the company is creating a financial account designed for the needs of AI, extending work already underway with agent wallets and stablecoin payment tools that support software-based trading and transactions.
Coinbase ramps up agentic wallet infrastructureCoinbase has been working to integrate digital asset management solutions for AI agents. Its Agentic Wallets, introduced in February, enable autonomous spending, earning, and trading, while incorporating security safeguards. These wallets allow software agents to make payments directly, addressing a key limitation where agents previously could only recommend actions rather than execute them independently.
Building on the infrastructure for AI systems, Coinbase for Agents was launched in June. This service lets approved AI agents connect to Coinbase user accounts and perform trades or make payments within limits set by human users. The coming expansion will see these capabilities scale up from wallets to broader AI-oriented financial accounts, following Coinbase’s ongoing product development strategy rather than introducing a completely new model.
Coinbase is building the financial account for AI, aiming to streamline how autonomous agents manage assets, make payments, and execute trades under secure, user-defined conditions.
Rise of AI agents in global paymentsAutonomous agents increasingly require the ability to purchase computing power, access APIs, and pay for various digital services directly. To address this, Coinbase developed the x402 protocol, which supports machine-to-machine payments in stablecoins like USDC. This infrastructure allows agents to transact with digital services seamlessly, reducing the need for human intervention in routine purchases.
In May, Coinbase reported processing over 100 million payments through the x402 protocol, with more than 99% settled in USDC. While not all these transactions involved AI agents, the volume underscores the scalability and adoption of its machine-oriented payments platform.
Mini dictionary: x402 protocol, a Coinbase-developed payments layer allowing autonomous machine-to-machine stablecoin transfers and designed to serve the transactional needs of digital and AI agents.
Payment protocolTotal paymentsMain stablecoin usedx402100 million+USDC (99%+)Stablecoins power autonomous agent transactionsStablecoins have played a central role in Coinbase’s approach, supporting dollar-denominated transfers across blockchain networks without relying on conventional banking or card systems. Coinbase has integrated USDC and other stablecoins within its payment platform, while its Base network serves as an Ethereum-layer-2 solution for processing these transactions efficiently.
The payments stack now supports both agent-initiated and enterprise-focused payment flows, aiming to make programmable payments accessible for software-driven activity. Expanding these capabilities enables a broader range of financial activity by autonomous agents across digital platforms.
Agentic finance becomes wider strategy for CoinbaseCoinbase is advancing its agentic finance model across trading, payments, and comprehensive financial management. Its broader vision connects autonomous agents with user accounts and introduces tools like Advisor, an AI-powered interface for retail users. Coinbase has also upgraded its business payments system to enable AI-initiated transactions at scale.
Financially, Coinbase reported a third consecutive record for quarterly crypto trading volume market share in the second quarter, reflecting a push to diversify products beyond traditional trading in response to evolving market dynamics.
Shares of Coinbase closed at $190.02 on September 29, slipping 0.92% that day. However, this decline cannot be directly linked to the agentic finance developments.
As Coinbase advances its agent-focused roadmap, the main challenge will be developing a scalable, secure financial framework for software agents. Issues such as identity verification, spending control, liability, fraud prevention, and regulatory compliance are expected to take on greater significance as autonomous agents gain more financial independence.
The company’s expansion moves from agent-specific wallets toward comprehensive accounts, aiming to form the backbone of non-human economic activity in digital finance.
Na Trumpově obědě o AI chyběl Apple, zatímco ostatní velcí technologičtí hráči se zúčastnili a podepsali dohodu o bezpečnostních opatřeních. Absence vyvolala spekulace, že Apple v oblasti AI zaostává.
When President Donald Trump gathered execs from the world's most powerful tech companies in the White House on Tuesday to discuss the future of artificial intelligence, one company was conspicuously absent: Apple.
Neither Chairman Tim Cook nor his successor as CEO, John Ternus, were present, while leaders from every other tech megacap – and many other companies – lunched with Trump.
Apple didn't respond to CNBC's questions about the meeting, nor did the White House.
Social media buzzed with conjecture that Apple wasn't invited because the company is behind on AI.
Altimeter Capital CEO Brad Gerstner, a powerhouse investor in Silicon Valley and a Trump ally in the second term, called Apple's absence a "nothing burger" int an interview with CNBC's "Squawk Box" on Wednesday.
"I can assure you, they're very much read in on all of this, and I suspect they agree with all of it," Gerstner said.
Cook, as Apple's public face with government officials around the world, was at the White House less than a week ago, when he attended Trump's state dinner with Chinese President Xi Jinping, Gerstner pointed out.
Cook stepped down as Apple CEO in September, handing the baton to hardware specialist Ternus.
As part of the transition, Apple noted that Cook would still handle "engaging with policymakers around the world" as the company's executive chairman. His new role was underscored last week at the state dinner with Xi.
Over the years, Cook has put in the time to maintain a good relationship with Trump. He's made over 10 public appearances at events in the president's second term, including Trump's inauguration, in the oval office, at Davos, and at state dinners on multiple continents. He attended the "Melania" screening at the White House.
Throughout his dealings with Trump over the past two years, Cook has stayed on message, focused on Apple's manufacturing interests and trade issues, at a time where its products could be subject to tariffs. The company has given the Trump administration wins on issues like American investment and jobs while trying to ward off Trump's longstanding desire for the company to make iPhones in the U.S.
More recently, Apple has reportedly sought to use Chinese-made memory chips as prices skyrocket around the world, but doing so requires a license. Commerce Secretary Lutnick said in an interview with the Wall Street Journal that "the Trump administration is not in favor of that."
A different approachGerstner, in his CNBC interview, said that the participants at the lunch were the companies that were "really pushing the frontier on model development."
That's not Apple.
The iPhone makers' in-house models are smaller and more efficient than the so-called "frontier" models developed by the likes of OpenAI and Anthropic, which were both represented. Apple Foundation Models are mostly designed to run on Apple's own silicon inside iPhones and Mac computers. They run parts of Siri, while OpenAI and Anthropic's models use massive Nvidia-based clusters of chips.
Apple is a consumer company, whereas most of the frontier lab AI competition happens in the enterprise. Apple partners with Google to develop its models. Its capital expenditures are tiny compared to the sums Google, Microsoft, Meta, and Amazon are investing.
While some investors fret that Apple is falling behind in AI, the market has increasingly seen it as a hedge to other capex-heavy tech names. And the company just launched a new AI-powered Siri earlier to mostly positive reviews.
watch now
Apple's stock is up 22.5% so far in 2026, outpacing the Nasdaq and almost all of its megacap peers other than Nvidia, which is up about the same amount.
Though Apple is very much touting the power of AI and its role in the technology's future, company executives have been mostly absent from the public debate around AI safety or alignment, which were primary topics at Trump's luncheon.
Nobody at Apple has penned the long manifestos like the ones coming from OpenAI, Anthropic, Meta, Microsoft and others.
As part of Tuesday's meeting with Trump, the White House and the leading AI companies signed an accord, committing the industry players to various safety measures. After the meeting Nvidia CEO Jensen Huang, OpenAI COO Greg Brockman, Meta CEO Mark Zuckerberg, Google CEO Sundar Pichai and Anthropic CEO Dario Amodei all signed the document.
Cook has said several times over the years that Apple is more likely to weigh in publicly on policy that "intersects with our company in some way." Apple's not dealing with alignment issues on the frontier.
"If it doesn't intersect — if it's something where we would just be another voice out there and not have a unique perspective to bring — then we don't say anything," Cook said in a 2021 DealBook interview.
Federal Realty Investment Trust oznámí výsledky za 3. čtvrtletí 2026 před otevřením trhu 30. října 2026. Téhož dne v 9:00 ET uspořádá konferenční hovor.
, /PRNewswire/ -- Federal Realty Investment Trust (NYSE:FRT) will announce its third quarter 2026 earnings results before market open on Friday, October 30, 2026. The Company will host a conference call on Friday, October 30, 2026 at 9:00 AM ET.
A replay of the webcast will be available 30 minutes after the conclusion of the call on Federal Realty's website at www.federalrealty.com. A telephonic replay of the conference call will also be available through November 13, 2026 by dialing 1-844-512-2921 or 1-412-317-6671; Passcode: 10211075
About Federal Realty
Federal Realty is a recognized leader in the ownership, operation and redevelopment of high-quality retail-based properties located primarily in major coastal markets and select underserved regions with strong economic and demographic fundamentals. Founded in 1962, Federal Realty's mission is to deliver long-term, sustainable growth through investing in communities where retail demand exceeds supply. This includes a portfolio of open-air shopping centers and mixed-use destinations—such as Santana Row, Pike & Rose, and Assembly Row—which together reflect the company's ability to create distinctive, high-performing environments that serve as vibrant destinations for their communities. Federal Realty's 103 properties include approximately 3,700 tenants in 28.8 million commercial square feet, and approximately 2,700 residential units.
Federal Realty has increased its quarterly dividends per common share for 59 consecutive years on an annualized basis, the longest record in the REIT industry. Federal Realty is an S&P 500 index member and its shares are traded on the NYSE under the symbol FRT. For additional information about Federal Realty and its properties, visit www.federalrealty.com.
Micron uvedl, že poptávka po AI infrastruktuře sílí do let 2027 a 2028, zatímco nabídku dál brzdí kapacity a složitější HBM čipy. Firma už má zajištěno přes 75 % plánovaných dodávek pro fiskální rok 2027.
SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit StoryMicron Technology NASDAQ: MU executives said demand tied to artificial intelligence infrastructure is strengthening into 2027 and 2028, while industry supply remains constrained by cleanroom capacity, increasingly complex high-bandwidth memory products and diminishing returns from technology transitions.
During the company’s fiscal fourth-quarter analyst call, President and Chief Operating Officer Manish Bhatia said Micron has committed more than 75% of its planned shipments for fiscal 2027. That visibility has allowed the company to begin allocation discussions with customers for 2028, he said.
Get Micron Technology alerts:
3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One“We really do not have line of sight to when supply and demand balances,” Bhatia said, citing the combination of stronger demand and structural constraints on supply growth.
AI Demand Expands Beyond Accelerators Bhatia pointed to continued server-unit growth and the spread of agentic AI workloads as major demand drivers. He said agentic AI is creating a CPU-driven source of demand in addition to the memory needs associated with AI accelerators.
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In ItAccording to Bhatia, agentic workloads require significant attachments of LP memory, DDR memory and solid-state drives. He said server units are growing in the high teens, while customers are currently seeking to maximize the amount of compute silicon they can ship with available memory supply.
That situation has created latent demand for additional memory, executives said. If more memory became available, customers could add more memory to AI systems and improve system performance.
Bhatia also said the company sees DRAM as the principal constraint on data-center expansion rather than logic or power. He cited the rapid adoption of enterprise and consumer agentic software as evidence of the demand environment.
HBM Remains a Key Growth Product Micron expects high-bandwidth memory, or HBM, shipments to grow faster than conventional DRAM through 2028. Bhatia said the product category will therefore represent a growing share of industry capacity.
The company said it significantly increased HBM pricing for calendar 2027, with the change intended to narrow the profitability gap with conventional DRAM. Micron did not provide an updated estimate for the HBM total addressable market, nor did it provide a specific HBM market-share target.
Bhatia said Micron expects its HBM share to remain around its broader DRAM market share, though he noted that the result may vary based on several factors. He said the company had reached its prior goal of bringing HBM share to its broader DRAM share about a year earlier.
Scott DeBoer, Micron’s President and Chief Technology and Products Officer, said the company has worked with NVIDIA for more than a year on HBM4E, referred to as NVHBM. He characterized it as the first major custom HBM product expected in the market and said the co-designed product could provide value beyond standard HBM4E.
DeBoer clarified that the HBM4E co-design uses a foundry process for both customized and JEDEC-specified products, rather than Micron’s in-house optimized base die approach used with HBM4. He said Micron seeks differentiation through power efficiency, speed performance, product margin and product quality.
Supply Agreements and Capacity Investments Micron said its supply-chain agreements, or SCAs, cover both DRAM and NAND. The company has discussed a goal of SCAs covering 35% of sales by 2030, though Bhatia said Micron was not breaking out the agreements by product category.
He said DRAM bit volume covered by the agreements is somewhat below approximately 35%, while NAND bit volume is somewhat above that level. The company has SCAs across all business units, including mobile and client markets, and said it signed 10 new customers during the quarter.
Most pricing frameworks in the agreements use floors and ceilings, Bhatia said, while approximately one-quarter of SCA revenue has pricing subject to periodic negotiations tied to market conditions. Newer agreements reflect higher current market pricing and Micron’s outlook for future tightness, he added.
Micron is increasing construction capital expenditures primarily to accelerate cleanroom availability beginning in late 2028 and beyond. Bhatia said these investments will not immediately translate into bit production, as fabs must still be equipped and qualified before meaningful shipments begin.
Chief Financial Officer Mark Murphy said most of the planned capital-expenditure increase is directed toward construction rather than equipment. Micron plans to equip cleanrooms and add production capacity based on demand trends, executives said.
Technology, China Exposure and Near-Term Modeling Items DeBoer said Micron’s technology lead over Chinese competitors is currently at least two DRAM nodes. He said Micron’s 1-gamma DRAM technology has become the majority of its bit output and is on track to become the largest node in company history. The company’s next-generation 1-delta node is under development, with a ramp targeted for the second half of next year.
Micron expects China exposure to fall into the single-digit percentage range in fiscal 2027, Bhatia said.
In mobile and client products, Micron reported sequential bit declines but revenue growth driven by higher pricing and favorable mix. Bhatia said premium PCs and flagship smartphones continue to show robust demand for higher-content, higher-performance memory, even as unit volumes decline.
For the fiscal first quarter, Murphy said Micron’s guidance assumes single-digit sequential bit growth and double-digit cost growth for both DRAM and NAND. He also said that, excluding incentive-compensation effects, the company expects its year-over-year research-and-development spending increase to exceed $1 billion in fiscal 2027 as it expands R&D activities.
About Micron Technology (NASDAQ:MU)Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage solutions. Its product portfolio includes dynamic random-access memory (DRAM), NAND flash memory, three-dimensional XPoint-related technologies, solid-state drives, and high-bandwidth memory products designed for demanding computing applications.
The company serves customers across the data center, artificial intelligence, networking, automotive, industrial, mobile, consumer electronics, and embedded markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Micron Technology Right Now?Before you consider Micron Technology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Micron Technology wasn't on the list.
While Micron Technology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Uniswap Labs připravuje nový hook pro Uniswap v4, který by vyplácel odměny v OUSD přímo poskytovatelům likvidity v oprávněných poolech. Cílí hlavně na páry se stablecoiny.
Uniswap Labs is developing a new hook for Uniswap v4. It would pay OUSD rewards directly to liquidity providers on eligible pools.
OUSD is Origin Dollar, a yield-bearing stablecoin. The planned feature would give liquidity providers a way to earn beyond the trading fees that have traditionally been their main source of income on the exchange.
How the OUSD rewards hook would work Hooks are an extensible architecture in Uniswap v4. They allow custom logic to run during pool events such as trades and changes to liquidity positions.
The OUSD rewards hook would use that system to deliver Origin Dollar incentives to liquidity providers in qualifying pools. Rather than relying on a separate rewards program layered on top, the distribution logic would live inside the pool mechanics.
The initiative is aimed mainly at trading pairs involving stablecoins.
The project remains in early planning. As of September 2026, Uniswap Labs has not disclosed a specific rollout date for the OUSD rewards mechanism.
Part of a broader push around v4 and stablecoins The OUSD hook is not arriving in isolation. It follows the launch of the StablePair Hook in September 2026, which brought dynamic fees to stablecoin transactions on Uniswap v4.
Uniswap has also worked on the user side of the equation. Its web application added tools in 2025 that give liquidity providers better visibility into their rewards.
What this means for liquidity providers and DEX competition The most direct effect, if the hook ships, would land on stablecoin pools. An extra stream of OUSD rewards could draw more liquidity providers looking for yield on top of fees.
There is a structural angle worth noting. Pairing a rewards token that is itself a yield-bearing stablecoin with stablecoin pools creates a fairly coherent product for conservative DeFi users.
For the wider DEX market, the bigger story may be the model rather than the specific token. Uniswap is showing how hooks can deliver targeted, pool-level rewards built directly into the exchange’s architecture.
For now, the key things to watch are a rollout date, the list of pools that qualify, and how the OUSD rewards are sized and distributed.
Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.
Filecoin spustil nové nástroje pro ukládání dat v IPFS s on-chain důkazem a cenou zhruba třetiny nejlevnější pinning alternativy. Nově lze migrovat existující CID i připínat nová data přes Filecoin Pin, který je dostupný jako CLI, JS knihovna a GitHub Action.
Filecoin was built from day one to persist the InterPlanetary File System (IPFS): cryptographic proof that content-addressed data is actually still there. That's been the idea since before the network existed. Thousands of developers already rely on IPFS to host websites, apps, datasets, and agents, and today new tools make that premise ready to use right now.
Storing IPFS data? You might be paying too much to pin. IPFS doesn't promise that your data sticks around on its own. Nothing on the network is obligated to keep a copy, so most people pay a pinning service (such as Pinata, or previously Infura or Storacha) to guarantee their files stay hosted and reachable, the way you'd pay for web hosting. You can now get that same guarantee from Filecoin: your pinned IPFS data, same CIDs, no changes needed, at roughly a third the cost of the cheapest pinning alternative we compared.
Step one: Meet IPFS → Filecoin Migrate your existing CIDs from any public IPFS gateway.
Your CIDs don't change. Nothing is re-chunked. Every CID stays byte-identical and keeps resolving from any public IPFS gateway. A fraction of pinning-service pricing. $2.50 per TiB per month per copy, two copies by default. You pay storage providers directly, streamed per epoch, with no plan tiers and no minimum commitment. Verifiable proof. Storage providers prove possession onchain on a schedule. You get a receipt with transaction links, and you can check any piece yourself. Your wallet holds it. No signup and no vendor account to lose. The data set belongs to your wallet address. Reading never touches your key. Retrieval works straight from any public IPFS gateway, so your content stays reachable no matter what happens to that wallet. If you're already paying a vendor to pin data you don't fully control, this is a way to keep the same links working while holding the guarantee yourself, at a fraction of the price.
The process is scriptable, too. You can hand a coding agent like Claude Code or Cursor a single line and let it read the migration guide and run the steps itself.
Step two: pin everything new on Filecoin Pin from now on. Filecoin Pin connects IPFS and Filecoin directly, persisting content-addressed data on a verifiable storage network, with no separate migration step required.
It's available now as a CLI, JS library, and GitHub Action, with dedicated migration guides for moving pins from any IPFS gateway, including a command-line walkthrough.
You use Filecoin Pin the way you'd use any pinning service. The difference is what's underneath: proofs run onchain where anyone can check them, and the storage itself is spread across a decentralized network of providers instead of living on one company's servers.
When you pin a file through Filecoin Pin, your IPFS content is uploaded to an audited Filecoin storage provider. Each provider must verify continuous data storage and access. Payments and uptime are handled automatically through Filecoin Pay. If proofs fail, streaming payments pause.
Who's already migrating to Filecoin Teams are already choosing to store their pinned IPFS data on Filecoin, from NFT platforms to institutions with legal and compliance obligations around their data.
Large-scale content platforms. Some products embed IPFS CIDs directly into customer-facing records at a scale where a single point of failure becomes a real production risk. NFT platforms are a great example: metadata and media for millions of live tokens, all needing to keep resolving indefinitely. Moving that volume onto Filecoin trades a vendor's uptime promise for onchain proof and a network of dedicated storage providers. NFTs2Me is a no-code NFT creation platform with more than 2.17 million IPFS CIDs associated with NFT artwork and metadata, now using Filecoin as its storage layer.
"We're responsible for the metadata behind millions of live tokens, and it all has to keep resolving. Filecoin gives us onchain proof that data is stored and available, backed by a global network." - The NFTs2Me Team
Legal and institutional recordkeeping. Some organizations reference IPFS links in legal, regulatory, or fiduciary contexts, where a document that stops resolving can mean a broken chain of evidence. For teams like DI GEA Trusts Confederation, persistence is a requirement. Onchain proof gives them something a standard pinning service can't: independent, checkable evidence that the document is still there, rather than a vendor's word for it. This is what brought DI GEA Trust Confederation storing legal and fiduciary documents referenced in court and tribunal contexts onto Filecoin.
"Our documents get referenced in legal and regulatory contexts years after they're filed, so we need real proof they're still there. Filecoin gives us onchain verification we can check ourselves, which is exactly the guarantee our fiduciary work requires." - The DI GEA Trusts Confederation Team
The infrastructure IPFS gateways sit on is evolving IPFS public gateway infrastructure is changing but whatever happens at the gateway layer, the CIDs themselves don't have to depend on it. Once your data is on Filecoin, it stays stored, verifiable, and retrievable.
Migrate your CIDs to Filecoin here: https://filecoin.cloud/ipfs2filecoin
Avalanche po aktivaci upgradu Helicon na mainnetu zrychlil verifikaci bloků na C-Chain zhruba na 2 milisekundy z asi 210 milisekund. Jde o přibližně 100násobné zlepšení.
Avalanche (@avax) has rolled out one of the most significant performance upgrades in its history. Since the Helicon upgrade activated on mainnet on September 22, the network's C-Chain now verifies blocks in roughly 2 milliseconds, down from approximately 210 milliseconds before the release. That is a roughly 100-fold improvement in block verification speed.
What Continuous Execution Actually Does The speed gain comes from a mechanism called Continuous Execution, introduced under community proposal ACP-194. The result is that the two processes no longer block each other, freeing up significant throughput headroom.
There is one practical nuance for developers to note:
Staking Rules Get a Significant Overhaul Helicon also rewrites validator economics.
The looser entry conditions come paired with a tighter performance requirement. Helicon also introduces a dynamic minimum gas price, replacing the network's previously fixed fee floor with a stake-weighted median set by validators.
Sources:
Avalanche Developer Blog: Helicon Upgrade Overview
Crypto Briefing: Avalanche activates Helicon upgrade, claims up to 100x faster block verification
Crypto Briefing: Avalanche activates Helicon upgrade, enhancing staking and execution
Anza navrhuje SIMD-0675, které by Solanu seřadilo validátory podle geografické polohy a zkrátilo prodlevy při předávání produkce bloků o 53 % v simulaci na datech z mainnetu.
Validátoři bez registrace lokace by byli z produkce bloků i hlasování vyloučeni.
Solana’s validators take turns producing blocks, and right now the order of those turns has nothing to do with where anyone actually lives.
Anza’s research team wants to shrink that toll. Its proposal, SIMD-0675, would line up validators that sit close to each other so they produce blocks back to back. In a simulation built on real mainnet data, the change cut block production handover delays by 53%.
What Anza is proposing The work comes from Anza researchers Quentin Kniep and Roger Wattenhofer. They authored two Solana Improvement Documents, known as SIMDs, which are the formal channel for suggesting protocol changes.
The two documents are SIMD-0674 and SIMD-0675. Both were opened on approximately 29 September 2026.
Together, they describe a system where validators register their geographic location on-chain. The network then uses those locations to build what the authors call a geo-aware leader schedule.
Every handover involves some waiting. The incoming leader needs the previous leader’s work before it can build on top of it, and distance stretches that wait.
The current schedule is random with respect to geography. The proposed one groups validators into geographic bins and runs them consecutively, so the baton mostly passes between neighbors instead of across the planet.
Advertisement
The design caps each bin at a maximum of 3 consecutive leaders. A full run through a region lasts approximately 2.4 seconds before the schedule moves on.
The numbers behind the pitch The researchers tested the idea against mainnet data from epoch 1038, which involved 661 validators.
Under the existing random scheduling, mean leader handover latency came in at 36.2 milliseconds. Under the geo-aware model, it dropped to 17.0 milliseconds.
That is the 53% improvement.
One detail matters a lot for validators worried about their revenue. According to the proposals, stake weights and slot allocations stay exactly the same.
Every validator keeps its original share of slots. The proposal only reshuffles when those slots occur, not how many each validator gets.
There is a catch, and it is not a small one. Validators that choose not to register a location would be excluded from block production and voting.
On process, SIMD-0675 moved to “ready for review” status on 30 September 2026 at 14:27 UTC. SIMD-0674 remains in draft.
Why Alpenglow makes this urgent The timing is not random, even if the current leader schedule is. The proposals are tied to Alpenglow, Solana’s upcoming consensus protocol.
Alpenglow aims for finality of around 150 milliseconds. Finality is the point at which a transaction is considered permanent and cannot be reversed.
The protocol was transitioning into testnet and devnet environments in late September 2026, right as these SIMDs appeared.
When your total finality target is measured in the low hundreds of milliseconds, a handover that eats tens of milliseconds is not background noise. It is a meaningful slice of the whole budget.
What this means for validators, builders and SOL holders For validator operators, the biggest shift is disclosure. Registering a physical location on-chain becomes the price of admission for producing blocks and voting.
The near-term milestones are clear enough. Watch how the community responds to SIMD-0675 now that it is open for review, and whether SIMD-0674 moves out of draft.
Also watch Alpenglow’s progress through testnet and devnet. If that protocol keeps advancing, pressure to squeeze out delays like handover latency will only grow.
Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.
NetApp představil Novus, novou architekturu pro AI továrny a GPU clustery nad 100 000 GPU. Cílí na až 100 TB za sekundu a zettabajtový souborový systém.
5 Tech Stocks Holding Their Ground Through the AI Trade PullbackNetApp NASDAQ: NTAP used its INSIGHT 2026 event to outline a strategy for helping enterprises prepare data infrastructure for agentic AI, announcing expanded cloud partnerships, enhancements to its AI Data Engine and management platform, and a new high-scale storage architecture called NetApp Novus.
George Kurian said organizations seeking to move AI projects from pilot programs into production face two core issues: infrastructure constraints and difficulty harnessing fragmented enterprise data. He said AI systems require increasingly large GPU clusters and datasets, while unstructured information remains dispersed across storage systems, clouds, remote offices and sovereignty jurisdictions.
Get NetApp alerts:
Is Backblaze the Next Momentum Monster?“Data is becoming the constraint to productively scale AI,” Kurian said. He cited NetApp’s view that 93% of organizations report at least one data challenge blocking their AI ambitions.
AI Data Engine expands beyond NetApp data Syam Nair, NetApp’s Chief Product Officer, said the company’s platform is intended to provide AI-ready data, proactive protection, unified storage and complete control across hybrid environments. He said the goal is to activate data where it resides rather than require customers to copy or migrate it.
Semtech Stock Climbs as AI Boom Drives Turnaround SuccessNair announced that the metadata capability of the NetApp AI Data Engine will support heterogeneous data sources, extending beyond NetApp-managed data. The software-defined capability is designed to discover, understand and activate data across an enterprise estate without moving it into another system, according to Nair.
NetApp said it will make the AI Data Engine and its new metadata capability available free for the first six months. Nair said the platform is intended to surface data patterns and context while applying governance and protection policies.
The company also highlighted its acquisition of DataPelago. Nair said DataPelago is designed to accelerate existing tools used by researchers and data teams, including Spark, Trino and Python libraries, within the data infrastructure and without code changes.
Security, recovery and hybrid management Nair said NetApp is pursuing what it calls “zero trust data security,” with protection built into data rather than centered solely on network posture or identity checks. He said AI readiness and data protection must operate together because autonomous agents could act on compromised information at machine speed.
NetApp also described expanded integration with Commvault. According to Nair, potential ransomware attacks will be surfaced within the Commvault interface, while NetApp’s SnapRestore and curated clean recovery capabilities will support recovery workflows.
For hybrid infrastructure management, the company introduced the NetApp Console, which Nair described as a control plane for on-premises systems, Keystone and major public clouds. The console includes AI-assisted operations intended to predict issues, resolve incidents and optimize capacity and costs with human oversight.
NetApp said the console can also operate in local, air-gapped environments. Nair said existing Active IQ Unified Manager customers will have an upgrade path rather than need to replace their management tooling.
The company additionally unveiled Keystone Sovereign, an add-on entitlement for Keystone subscriptions aimed at European Economic Area customers with regional compliance and data-residency requirements. Nair said the offering will be available in early November for France and Germany, followed by broader availability later.
Cloud partnerships expand Mahesh Thiagarajan, executive vice president of Oracle Cloud Infrastructure at Oracle, said Oracle and NetApp are partnering to bring ONTAP to OCI. He said OCI File Storage and NetApp ONTAP will soon enable customers to run business-critical file-storage workloads in OCI using ONTAP tools, APIs and automation.
Thomas Kurian, CEO of Google Cloud, said Google Cloud NetApp Volumes supports enterprise workloads, agentic workloads and retrieval-augmented generation inferencing. He also said NetApp storage solutions are now embedded natively in Google Distributed Cloud, supporting air-gapped sovereign environments for Google AI models.
Scott Guthrie, executive vice president of Microsoft Cloud, said Microsoft and NetApp continue to help customers bring ONTAP workloads to Azure and run demanding workloads through Azure NetApp Files.
NetApp introduces Novus for AI factories The event’s largest announcement was NetApp Novus, a new disaggregated architecture intended for accelerated computing environments, large AI factories and GPU clusters exceeding 100,000 GPUs.
Kurian said Novus is designed to independently scale storage components and assimilate data across tens of thousands of systems into a single namespace. NetApp said the architecture is designed to deliver up to 100 TB per second of performance and a zettabyte-scale file system, claims the company characterized as first-of-their-kind capabilities.
Arindam Banerjee, NetApp’s Chief Platform and Technology Officer, said Novus uses federation to combine multiple storage clusters into one namespace, with throughput increasing as clusters are added. The architecture uses standard pNFS and Flex Files protocols, he said, allowing use of the stock Linux kernel rather than requiring a proprietary client or kernel module.
Banerjee said Novus separates metadata services into independently scalable protocol, state and catalog planes, addressing metadata bottlenecks that can arise when AI workloads combine high-volume data reads and writes with extensive metadata operations. Novus data servers will run ONTAP, he added, extending NetApp’s existing data integrity, resilience, security, isolation and quality-of-service capabilities to the new architecture.
Kurian said the announcements reflect NetApp’s effort to help customers build intelligent data infrastructure that can transform enterprise data into usable knowledge for AI systems and agents.
About NetApp (NASDAQ:NTAP)NetApp, Inc develops intelligent data infrastructure and data management solutions for enterprises, service providers, and government organizations. The company helps customers store, manage, protect, and access data across on-premises environments, private clouds, public clouds, and hybrid multicloud infrastructures.
Its portfolio includes enterprise storage systems, all-flash arrays, cloud-connected storage, object storage, and data management software. NetApp's offerings include the ONTAP data management operating system, AFF and ASA storage systems, StorageGRID object storage, and BlueXP, a platform designed to help customers manage data and storage resources across multiple environments.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in NetApp Right Now?Before you consider NetApp, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NetApp wasn't on the list.
While NetApp currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Uber plánuje nasadit nejméně 10 000 autonomních vozů Rivian R2 a může přikoupit až 40 000 dalších od roku 2030. Pro Rivian to může otevřít trh robotaxi.
Rivian Automotive (RIVN -0.20%) has spent years trying to become a major player in the electric vehicle market. Now a new deal with Uber (UBER -1.23%) could open the door to an entirely different opportunity: robotaxis.
Uber plans to deploy at least 10,000 autonomous Rivian R2 vehicles, with the option to purchase as many as 40,000 more beginning in 2030. That's huge! Uber is also prepared to invest up to $1.25 billion in Rivian through 2031, although most of that money is tied to Rivian hitting specific autonomous-driving milestones. For a company expected to deliver only 65,000 to 70,000 vehicles in all of 2026, this is not trivial.
Premium Feature
Moneyball Superscore
79/100
Today's Change
(
-1.23
%) $
-0.85
Current Price
$
68.51
More than an EV company To be sure, Rivian still needs to prove it can profitably manufacture electric vehicles at scale. In Q2, the company delivered 12,194 vehicles and generated $1.66 billion in revenue. It posted a $179 million gross profit, but its automotive business still recorded a $36 million gross loss. Rivian also burned through $849 million in free cash flow during the quarter. But robotaxis could give Rivian another way to make money from the technology it's already developing.
Premium Feature
Moneyball Superscore
64/100
Today's Change
(
-0.20
%) $
-0.03
Current Price
$
14.94
Rivian's newest autonomy platform goal is eventually to reach level 4 autonomy. At this level, a vehicle can drive itself without a human, but only within defined operating conditions.
Rivian is also selling Autonomy+, its advanced driver-assistance software, for $49.99 per month or $2,500 upfront. That starts to move Rivian beyond the economics of simply building a vehicle and collecting a one-time sale.
The Uber deal changes the equation Uber brings something Rivian doesn't have: enormous ride-hailing scale. Uber completed 3.9 billion trips in the second quarter alone, up 18% from a year earlier. If Rivian can successfully develop level 4 autonomy, Uber gives it a ready-made network that can put thousands of autonomous vehicles to work.
Image source: Getty Images.
Of course, there are still risks. Rivian hasn't yet demonstrated level 4 autonomy commercially, the first deployments aren't expected until 2028, and the additional 40,000 vehicles aren't guaranteed purchases. Still, the deal shows what Rivian could become.
The R2 may help Rivian reach a much larger consumer market. But if the same vehicle platform can also become the foundation for tens of thousands of autonomous taxis, Rivian won't just be selling EVs. It could also be selling the hardware and software that drive them. And that completely changes the game.
QNT po partnerství s The Clearing House vystřelil zhruba o 280 % za týden a pohybuje se kolem 300 USD. RSI je na 81,70 a otevřený zájem vzrostl na 86,3 milionu USD.
QNT’s breakout has evolved into a broader momentum trade after surviving a sharp pullback. Growing leverage could amplify volatility as traders chase the rally. Dormant supply is beginning to move as Quant returns to institutional focus. Quant has turned one institutional catalyst into one of crypto’s most aggressive rallies of the week.
QNT traded around $300 on Sept. 30, gaining roughly 13% on the day after moving as high as $326.54. The advance extends a weekly rally of more than 280% and has pushed Quant to No. 30 among cryptocurrencies by market capitalization.
The scale of the repricing is visible in the daily chart from TradingView. QNT spent much of September around $60-$70 before breaking above $100, accelerating through $150 and eventually printing an intraday wick above $360. Even after a violent retracement below $200, buyers returned and carried the token back toward $300.
Quant’s rally pushes the RSI deep into overbought territory as the MACD maintains strong bullish momentum. Momentum indicators now confirm just how stretched that move has become. QNT’s 14-day RSI has reached 81.70, firmly above the conventional 70 overbought threshold, while MACD remains strongly positive.
The rally began around Quant’s partnership with The Clearing House six days ago. Since then, however, it has acquired additional fuel from rising derivatives exposure, renewed institutional visibility and social momentum.
The result is a market that has moved well beyond simply reacting to a press release.
QNT’s Breakout Has Survived Its First Major Reversal The most revealing part of the chart is no longer the initial breakout.
It is what happened afterward.
QNT moved almost vertically from below $100 into the high-$200s before briefly trading above $360. That kind of expansion was followed by an equally aggressive rejection, with the token falling below $200 intraday.
Instead of returning toward its previous trading range, QNT recovered.
The Sept. 30 candle opened at $266.57, fell as low as $262.83 and reached $326.54 before settling around $300. That leaves the token roughly 13% higher on the session while challenging the same $300 area that previously attracted heavy volatility.
The recovery means QNT has retained a large portion of its breakout despite already experiencing a substantial correction.
But the indicators underneath price show that the market is far from normalized.
RSI at 81.70 Shows How Extended QNT Has Become QNT’s 14-day Relative Strength Index stands at 81.70.
An RSI above 70 is conventionally described as overbought, making the current reading unusually elevated. That does not mean QNT must immediately reverse. During powerful trends, RSI can remain above 70 for extended periods while price continues rising.
It does mean the token is trading with substantially stronger upward momentum than its recent historical range.
There is another useful detail in the chart.
The RSI’s moving average has climbed to approximately 70.02, meaning the underlying momentum trend has followed the indicator higher rather than QNT merely producing a single isolated spike.
MACD tells a similar story from another angle.
The chart shows the MACD line at 49.92, well above the 25.14 signal line, while the histogram remains positive at approximately 24.78.
That wide positive spread indicates that shorter-term momentum continues to run substantially ahead of the longer-term trend.
Taken together, the indicators describe an unusual combination:
QNT remains technically powerful, but it is no longer technically early. The breakout has momentum behind it. It also carries considerably more extension risk than it did near $100 or $150.
The Rally Started With a Banking Catalyst The initial repricing can be traced to Sept. 24.
The Clearing House selected Quant to provide the interoperability, orchestration and transaction-management technology behind its On-Chain Money Initiative, which is being developed to support tokenized commercial bank deposits. The Clearing House announcement
The significance comes from the infrastructure sitting behind the project.
The Clearing House operates major U.S. payment systems including RTP and CHIPS, while its On-Chain Money Initiative is intended to connect blockchain-based bank deposits with established banking infrastructure.
Quant is therefore not merely attached to a proof-of-concept carrying a large financial name. Its technology has been selected for a specific interoperability role in a bank-led tokenized-money network.
That provided QNT with a credible fundamental catalyst after months of relatively subdued trading.
It does not provide a valuation formula capable of explaining every dollar added to QNT since.
And six days into the rally, that distinction has become increasingly important.
$86 Million in Open Interest Adds Leverage to the Move The derivatives market is now reinforcing QNT’s volatility.
Data from Coinalyze for Sept. 30 show approximately $86.3 million in QNT open interest, an increase of 26.28% over 24 hours.
Most of that positioning sits on just two exchanges:
Binance: $54.1 million Bybit: $30.7 million Kraken: $1.6 million Huobi: $97,200 Binance and Bybit account for roughly 98% of the displayed total.
That matters alongside the technical indicators.
An RSI above 80 shows that spot momentum is already highly extended. Rising open interest means new leveraged positions are simultaneously being layered onto that move.
Neither metric independently predicts a reversal. But together they make QNT increasingly sensitive to sharp changes in positioning.
If momentum continues, leverage can reinforce the advance. If price reverses rapidly, the same derivatives market can accelerate the move through liquidations.
A Viral QNT Call Arrived During the Acceleration QNT’s rise has also acquired a social-media component.
On Sept. 26, gold analyst Jan Nieuwenhuijs urged followers to buy at least one QNT, presenting the position as roughly $120 of downside against a possible $10,000 payoff.
Today I advise everyone to buy at least 1 $QNT. Risk: loose $120, potential: earn $10,000. https://t.co/wPXwdsYJQE
— Jan Nieuwenhuijs (@JanGold_) September 26, 2026
The post spread partly because Nieuwenhuijs had made a bullish Bitcoin call in 2013.
That history makes for an effective social narrative, but it does not provide a valuation model for Quant. A previous successful Bitcoin call offers no evidence that QNT will reach $10,000.
The timing is more relevant.
His post appeared as QNT was accelerating out of its initial breakout. Price subsequently moved several times above the level around which the call was made.
The prediction therefore became attached to a rally that was already gathering momentum, helping turn QNT from an institutional-news story into a much more visible speculative trade.
Seven-Year-Dormant QNT Is Moving Again Rapid appreciation is also beginning to draw attention to dormant supply.
Lookonchain reported on Sept. 30 in X that a wallet linked to Quant’s founder transferred 25,776 QNT worth approximately $6.97 million after seven years without activity.
Arkham data shows a series of QNT transfers from a wallet labeled Quant Network The wallet still retained roughly 600,000 QNT, valued at approximately $160.39 million at the time of the report.
That transaction requires careful interpretation.
The transferred tokens moved to newly created wallets rather than directly to a centralized exchange. There is therefore no blockchain evidence from the transfer alone that they were sold.
What makes the movement relevant is its timing.
A previously dormant position has become active during QNT’s largest repricing in years, while a much larger balance remains associated with the original wallet.
The next movement of those tokens would consequently provide more useful information than the initial transfer itself.
Quant’s Institutional Story Is Still Developing Away from the chart, Quant is using Sibos 2026 in Miami to demonstrate how its infrastructure could operate inside another area of institutional finance.
Quant and Capgemini are presenting an agentic-AI treasury workflow capable of identifying liquidity shortfalls, evaluating balances and market conditions, and moving tokenized deposits when permitted by predefined controls.
Smaller liquidity gaps can be handled automatically in the demonstration. Larger funding decisions require human approval before the transaction proceeds.
Quant provides the tokenized-deposit issuance, workflow and policy infrastructure, while Capgemini developed the liquidity alerts, agent decisioning and approval experience.
The demonstration should not be treated as another direct source of QNT demand.
It does, however, reinforce the broader institutional narrative developing around Quant during the same week its token has returned to the center of crypto trading.
QNT Has Momentum, but It No Longer Has a Quiet Market The market that existed around QNT a week ago has disappeared.
A relatively subdued token near $70 has become a top-30 crypto asset trading around $300. Its RSI is above 80.
MACD remains strongly positive. Open interest is expanding. Social attention has surged. And previously dormant tokens are moving while Quant itself is appearing in increasingly prominent institutional-finance projects.
The indicators do not say that the rally is finished.
They say something more useful: QNT is now trading with both exceptional momentum and exceptional extension.
That makes the behavior around $300 particularly informative.
A sustained hold would show that buyers can retain much of the repricing even after the first major rejection from above $360. Another deep retracement would instead test how much of the vertical move was supported by durable demand once momentum cools and leveraged positioning is forced to adjust.
The Clearing House partnership explains why the market suddenly had a reason to look at Quant.
An RSI of 81.70, rapidly expanding leverage and a 280% weekly move show just how far traders have taken it since.
Alexander Zdravkov is a crypto journalist and market analyst specializing in digital assets, blockchain technology, and the rapidly evolving cryptocurrency market. He entered the industry more than four years ago, drawn to the speed of innovation in crypto and the potential of blockchain-based financial systems to reshape traditional markets. His work focuses on understanding the forces behind crypto market movements, from Bitcoin and altcoin cycles to institutional adoption, regulation, exchange-traded products, stablecoins, DeFi, and emerging blockchain ecosystems. Rather than simply following price action, Alexander looks at liquidity, investor positioning, market structure, and macroeconomic conditions to identify developing trends and explain what they could mean for digital assets. With a degree in International Relations, he brings a broader perspective to cryptocurrency coverage by connecting developments in the sector with monetary policy, geopolitics, regulation, and global capital flows. This allows him to examine crypto not as an isolated market, but as an increasingly interconnected part of the global financial system. Over the course of more than five years in financial journalism, Alexander has written over 5,000 articles covering cryptocurrencies, blockchain, traditional markets, and the global economy. His reporting spans Bitcoin, Ethereum and altcoins, DeFi protocols, institutional crypto adoption, regulation, market infrastructure, security incidents, and major developments shaping the wider digital asset industry. His approach is centered on giving readers context behind the numbers and headlines, explaining not only what is happening in crypto markets, but why it matters and what could come next.
The Clearing House zvolila Quant pro svou iniciativu On-Chain Money Initiative, která má bankám umožnit vypořádání tokenizovaných vkladů. Projekt podporuje 25 největších finančních institucí v USA.
When @TCHtweets announced on September 24 that it had chosen @quantnetwork to power its new tokenized deposit network, most coverage focused on what it meant for $QNT. The more instructive question is who The Clearing House actually is, and why its endorsement carries so much weight.
The Infrastructure Behind US Banking The Clearing House was founded in 1853 by 38 New York banks and served as a de facto central bank before the Federal Reserve existed. Today it is owned by the largest US commercial banks and sits at the center of the country's payment system.
It operates three core payment systems: CHIPS for large-value wire clearing, the EPN automated clearing house (ACH), and the RTP network, the private-sector real-time payments rail it launched in 2017. Its networks clear and settle more than $2 trillion per day across wire transfers, ACH, checks, and real-time payments. In 2024, EPN alone handled 20.7 billion payments worth $56.4 trillion, roughly half of all US commercial ACH volume. CHIPS is the largest private-sector USD clearing and settlement network in the world for high-value wire payments.
Why Quant Was Chosen The Clearing House selected Quant, described as a leading provider of programmable money infrastructure, to power its On-Chain Money Initiative, a new interoperable payments network that will enable financial institutions to clear and settle tokenized deposit transactions.
Tokenized deposits are digital representations of bank balances. A tokenized deposit remains a deposit liability of the bank that issued it, which distinguishes them from public stablecoins and preserves the existing protections depositors rely on.
Quant will handle the interoperability and transaction layer, linking the network to systems like RTP and CHIPS. The selection reflects Quant's positioning as a provider of programmable money infrastructure that supports interoperability across multiple ledgers rather than requiring institutions to commit to a single blockchain.
The initiative is backed by 25 of the country's largest financial institutions, naming Bank of America, Citi, J.P. Morgan, Wells Fargo, HSBC, BNY, PNC Bank, U.S. Bank, and Truist among others. The On-Chain Money Initiative is designed to create new opportunities across corporate treasury, liquidity management, cross-border payments, and digital asset settlement. The network is expected to become available to participating institutions in the first half of 2027.
Sources:
The Clearing House Partners with Quant to Advance the On-Chain Money Initiative (PR Newswire via Yahoo Finance)
TCH and Quant Partner to Power US Tokenized Deposit Network for Banks (FF News)
The Clearing House Payments Company (Wikipedia)
USA a Jižní Korea uzavřely rámcovou dohodu, která počítá až s 120 miliardami USD korejských investic na výstavbu osmi velkých jaderných reaktorů v USA, včetně šesti Westinghouse AP1000 a dvou korejských APR1400.
Framework commits up to $120 billion of Korean investment to support construction of new nuclear reactors in the United States
Builds on strategic partnership between the U.S. Government, Brookfield and Cameco to accelerate the deployment of Westinghouse nuclear technology
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brookfield Asset Management (“Brookfield”) today welcomed the new strategic framework agreement between the United States Government (“U.S. Government”) and the Republic of Korea (“Korea”) to support the deployment of Westinghouse technology in the United States (“U.S.”).
The framework agreement commits up to $120 billion of investment by Korea to help finance the construction of eight large nuclear reactors in the U.S., including six Westinghouse AP1000 reactors and two Korean APR1400 reactors which also incorporate Westinghouse technology. The reactors will be deployed on federal sites designated by the U.S. Government, using the capabilities and expertise of companies from both countries.
The framework agreement provides a defined pathway to support the construction of eight new reactors in the U.S., including six Westinghouse AP1000 reactors across three two-unit plants on U.S. federal sites. An additional two APR1400 reactors on U.S. federal sites will also be funded as part of the framework agreement, with Westinghouse benefiting from an upfront payment as well as guaranteed scope of work on the reactors, and a contract to provide fuel-fabrication services. Locating this new generation of reactors on federal sites provides a strategic opportunity to support the buildout of the power and compute infrastructure required to meet growing U.S. energy demand, including from AI.
The framework agreement also provides for a cornerstone equity investment of between 5% and 10% in Westinghouse by Korea, further aligning the parties around the long-term growth and deployment of Westinghouse technology.
Connor Teskey, CEO of Brookfield Asset Management, said: “Today’s announcement underscores why the U.S. is one of the most attractive markets in the world to build new nuclear generation. Bringing together the capabilities of the U.S. and Korea, with Westinghouse’s leading nuclear technology, will mobilize significant capital and accelerate deployment at scale. Brookfield has a long history of investing in the critical infrastructure that underpins the U.S. economy, and we look forward to working with our partners to support the expansion of America’s nuclear industry.”
Dan Sumner, President and Chief Executive Officer of Westinghouse, said: “Today’s announcement marks a defining moment for the future of U.S. nuclear energy and for the longstanding partnership between the United States and the Republic of Korea. The announcement also underscores the strategic importance of Westinghouse in the deployment of nuclear energy – we bring deep engineering expertise, a proven record of nuclear innovation and unmatched experience delivering advanced reactor technology in the U.S. and around the world.”
Building a new generation of U.S. nuclear capacity
Today’s announcement is the next step in the strategic partnership announced in October 2025 between the Department of Commerce, Westinghouse and its shareholders, Brookfield and Cameco, to fund the deployment of at least $80 billion of Westinghouse nuclear reactors in the U.S. on federal sites. This framework and funding commitment is separate and distinct from the Department of Energy’s strategic partnership announced in June 2026, including the $17.5 billion conditional loan funding arrangement to support the purchase of long-lead items. Collectively these frameworks underpin the U.S. commitment to significantly expanding nuclear generation capacity to meet rapidly growing demand for reliable, secure power, from electrification, reindustrialization and the buildout of AI and compute infrastructure.
Terms of the transaction are non-binding and are subject to final negotiations.
About Brookfield Asset Management
Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) is a leading global alternative asset manager, headquartered in New York, with over $1 trillion of assets under management across infrastructure, energy, private equity, real estate, and credit. We invest client capital for the long-term with a focus on real assets and essential service businesses that form the backbone of the global economy. We offer a range of alternative investment products to investors around the world – including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies and private wealth investors. We draw on Brookfield's heritage as an owner and operator to invest for value and generate strong returns for our clients, across economic cycles.
For more information, please visit our website at www.brookfield.com.
Notice to Readers
This press release contains “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of other relevant securities legislation, including applicable securities laws in Canada, which reflect our current views with respect to, among other things, our operations and financial performance (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, beliefs and assumptions and which are in turn based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. The estimates, beliefs and assumptions of Brookfield are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and as such, are subject to change. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions. In particular, the forward-looking statements contained in this press release include statements referring to the commitment size of the strategic partnership and its expected benefits, the number and type of nuclear reactors to be constructed, the timing and amount of the initial funding, the upfront payment, scope of work and contracts provided to Westinghouse, and the Republic of Korea’s equity investment in Westinghouse.
Although Brookfield believes that such forward-looking statements are based upon reasonable estimates, beliefs and assumptions, certain factors, risks and uncertainties, which are described from time to time in our documents filed with the securities regulators in the United States and Canada, not presently known to Brookfield or that that Brookfield currently believes are not material, could cause actual results or events to differ materially from those contemplated or implied by forward-looking statements.
Readers are urged to consider these risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements, which are based only on information available to Brookfield as of the date of this press release. Except as required by law, Brookfield undertakes no obligation to publicly update or revise any forward-looking statements, whether written or oral, that may be as a result of new information, future events or otherwise.
Silicon Motion (SIMO) uzavřel na 280,00 USD, což představuje denní růst o 1,39 % a překonání širšího trhu. Akcie za poslední měsíc vzrostly o 16,35 % a firma čeká EPS 3,3 USD a tržby 532,81 milionu USD.
In the latest trading session, Silicon Motion (SIMO - Free Report) closed at $280.00, marking a +1.39% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.25%. Elsewhere, the Dow saw a downswing of 0.86%, while the tech-heavy Nasdaq appreciated by 0.24%.
The chip company's shares have seen an increase of 16.35% over the last month, surpassing the Computer and Technology sector's gain of 4% and the S&P 500's loss of 0.42%.
The upcoming earnings release of Silicon Motion will be of great interest to investors. The company is forecasted to report an EPS of $3.3, showcasing a 230% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $532.81 million, showing a 120.17% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.16 per share and a revenue of $1.89 billion, signifying shifts of +214.37% and +112.86%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Silicon Motion. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Silicon Motion presently features a Zacks Rank of #1 (Strong Buy).
With respect to valuation, Silicon Motion is currently being traded at a Forward P/E ratio of 24.76. This signifies a premium in comparison to the average Forward P/E of 21.3 for its industry.
One should further note that SIMO currently holds a PEG ratio of 0.46. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Computer - Integrated Systems industry had an average PEG ratio of 0.67.
The Computer - Integrated Systems industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 74, this industry ranks in the top 31% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Meta Platforms (META - Free Report) ended the recent trading session at $725.18, demonstrating a -1.84% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.25%. On the other hand, the Dow registered a loss of 0.86%, and the technology-centric Nasdaq increased by 0.24%.
The stock of social media company has risen by 27.7% in the past month, leading the Computer and Technology sector's gain of 4% and the S&P 500's loss of 0.42%.
Investors will be eagerly watching for the performance of Meta Platforms in its upcoming earnings disclosure. The company is expected to report EPS of $6.39, down 11.86% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $63.18 billion, indicating a 23.3% growth compared to the corresponding quarter of the prior year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $31.39 per share and a revenue of $254.04 billion, representing changes of +33.63% and +26.41%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Meta Platforms. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.82% downward. Meta Platforms is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, Meta Platforms currently has a Forward P/E ratio of 23.54. This signifies a premium in comparison to the average Forward P/E of 18.78 for its industry.
One should further note that META currently holds a PEG ratio of 1.15. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Internet - Software industry stood at 1.15 at the close of the market yesterday.
The Internet - Software industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 86, finds itself in the top 35% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Nvidia (NVDA +0.52%), an AI chip and networking provider, closed at $228.38, up 0.51%. Premarket buyback headlines and a session update on its AI safety accord kept investors focused on capital returns and AI demand.
Trading volume reached 117.7M shares, coming in nearly 5.2% below its three-month average of 124.1M shares. Nvidia IPO'd in 1999 and has grown 556,695% since going public.
How the markets moved todayThe S&P 500 (SNPINDEX: ^GSPC) closed at 7,654, down 0.23%, while the Nasdaq Composite (NASDAQINDEX: ^IXIC) finished at 26,861, up 0.24%. Among semiconductor peers, Advanced Micro Devices (AMD +0.69%) closed at $611.76, up 0.69%, and Broadcom (AVGO -1.10%) closed at $351.19, down 1.10%, as investors tracked accelerated computing, GPU, AI, data-center networking, and related software demand.
What this means for investorsAlthough Nvidia stock rose only modestly today, it continues to ride high as it secures its future as one of the most essential AI companies. Its AI safety accord likely brings comfort to those concerned about out-of-control AI wreaking havoc on society.
That accord comes after Nvidia also solidified its place in the quantum computing industry last month by expanding Open-Source CUDA-Q to offer fault-tolerant quantum computing. This is significant takes its software platform beyond core GPUs.
Such breakthroughs seem to help boost its financials. Last week, it authorized an additional $150 billion in share repurchases, taking the total to $235 billion through 2028. To put that into perspective, just over 60 companies trading on U.S. markets have a market cap above $235 billion today.
It likely can afford to buy back shares as its revenue for fiscal Q2 (ended July 26) increased by 106% year over year. Despite that increase, its forward P/E ratio stands at just 25, a level that should boost the bull case in the chip stock for a long time to come.
Will Healy has positions in Advanced Micro Devices. The Motley Fool has positions in and recommends Advanced Micro Devices, Broadcom, and Nvidia. The Motley Fool has a disclosure policy.
In the latest close session, Visa (V - Free Report) was down 1.79% at $359.33. The stock trailed the S&P 500, which registered a daily loss of 0.25%. Meanwhile, the Dow lost 0.86%, and the Nasdaq, a tech-heavy index, added 0.24%.
The stock of global payments processor has fallen by 1.82% in the past month, leading the Business Services sector's loss of 5.76% and undershooting the S&P 500's loss of 0.42%.
The investment community will be paying close attention to the earnings performance of Visa in its upcoming release. The company is forecasted to report an EPS of $3.43, showcasing a 15.1% upward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $12.07 billion, indicating a 12.59% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $13.22 per share and revenue of $45.83 billion, which would represent changes of +15.26% and +14.58%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Visa. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.47% higher. Visa is currently a Zacks Rank #2 (Buy).
From a valuation perspective, Visa is currently exchanging hands at a Forward P/E ratio of 27.67. Its industry sports an average Forward P/E of 13.68, so one might conclude that Visa is trading at a premium comparatively.
It is also worth noting that V currently has a PEG ratio of 1.95. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Financial Transaction Services industry currently had an average PEG ratio of 0.76 as of yesterday's close.
The Financial Transaction Services industry is part of the Business Services sector. With its current Zacks Industry Rank of 166, this industry ranks in the bottom 33% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Merrill Lynch zaplatí 39 milionů USD za urovnání žaloby, že klientům z nevyužité hotovosti v důchodových účtech vyplácel téměř nulový úrok místo tržních úrokových sazeb.
Bank of America's (BAC.N) Merrill Lynch unit will pay $39 million to settle a class action claiming it paid brokerage customers near-zero interest rates instead of market rates on idle cash in their retirement accounts.
Settlement papers were filed late on Wednesday in Manhattan federal court. The settlement requires approval by US District Judge Valerie Caproni, averting a trial that had been scheduled for mid-October.
Holders of Merrill Edge online accounts between December 15, 2016 and March 15, 2020 accused Merrill Lynch of breaching its client agreements by automatically sweeping cash balances into deposit accounts that paid less than a "reasonable rate" of interest.
The complaint said the sweep accounts carried annual yields of 0.05% to 0.14%, while other brokerages were paying customers about 2%.
Merrill Lynch denied wrongdoing in agreeing to settle. A Bank of America spokesperson declined to comment. Lawyers for the brokerage customers did not immediately respond to requests for comment.
Many large banks and brokerages have been sued over low-yielding sweep accounts, especially in 2023 and 2024 when customers said those accounts were not keeping up with rising interest rates. The lawsuits have had mixed success.
In February, another Manhattan federal judge said JPMorgan Chase (JPM.N) must face part of one such lawsuit. On September 18, a third Manhattan federal judge granted final approval to a $70 million settlement with Oppenheimer & Co (OPY.N).
Royal Caribbean v poslední seanci vzrostla o 1,99 % na 265,86 USD, zatímco širší trh klesal. Před zveřejněním hospodářských výsledků analytici čekají EPS 6,36 USD a tržby 5,58 miliardy USD.
In the latest close session, Royal Caribbean (RCL - Free Report) was up +1.99% at $265.86. The stock outpaced the S&P 500's daily loss of 0.25%. On the other hand, the Dow registered a loss of 0.86%, and the technology-centric Nasdaq increased by 0.24%.
The stock of cruise operator has fallen by 1.89% in the past month, leading the Consumer Discretionary sector's loss of 8.16% and undershooting the S&P 500's loss of 0.42%.
Analysts and investors alike will be keeping a close eye on the performance of Royal Caribbean in its upcoming earnings disclosure. In that report, analysts expect Royal Caribbean to post earnings of $6.36 per share. This would mark year-over-year growth of 10.61%. Simultaneously, our latest consensus estimate expects the revenue to be $5.58 billion, showing a 8.66% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $17.79 per share and revenue of $19.58 billion. These totals would mark changes of +13.75% and +9.15%, respectively, from last year.
Investors should also take note of any recent adjustments to analyst estimates for Royal Caribbean. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.01% upward. Royal Caribbean currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Royal Caribbean has a Forward P/E ratio of 14.66 right now. This signifies a discount in comparison to the average Forward P/E of 15.04 for its industry.
Meanwhile, RCL's PEG ratio is currently 0.92. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Leisure and Recreation Services industry currently had an average PEG ratio of 1.2 as of yesterday's close.
The Leisure and Recreation Services industry is part of the Consumer Discretionary sector. At present, this industry carries a Zacks Industry Rank of 192, placing it within the bottom 22% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Synopsys uspořádal Investor Day a vedení představilo výhled, cíle a další výhledová prohlášení. Společnost zároveň upozornila, že výsledky se mohou od odhadů lišit.
Synopsys, Inc. (SNPS) Analyst/Investor Day September 30, 2026 1:00 PM EDT
Company Participants
Tushar Jain - Head of Investor Relations
Sassine Ghazi - CEO, President & Director
Shankar Krishnamoorthy - Chief Product Development Officer
Shelagh Glaser - Chief Financial Officer
Conference Call Participants
Lip-Bu Tan - Intel Corporation
Jin Han - Samsung Electronics Co., Ltd.
Greg Brockman - OpenAI, L.L.C.
Sitikantha Panigrahi - Mizuho Securities USA LLC, Research Division
James Schneider - Goldman Sachs Group, Inc., Research Division
Vivek Arya - BofA Securities, Research Division
Jay Vleeschhouwer - Griffin Securities, Inc., Research Division
Joshua Tilton - Wolfe Research, LLC
Jason Celino - KeyBanc Capital Markets Inc., Research Division
Lee Simpson - Morgan Stanley, Research Division
Andrew DeGasperi - BNP Paribas, Research Division
Yu Shi - Needham & Company, LLC, Research Division
Ashish Bhandari - Throughline Capital, LLC
Gary Mobley - StoneX Group Inc.
Presentation
Operator
Welcome to Synopsys Investor Day. [Operator Instructions] Today's program is being recorded and webcast live. Please welcome Tushar Jain, Vice President, Synopsys Investor Relations.
Tushar Jain
Head of Investor Relations
Thank you. Thank you, everyone. Good afternoon, and welcome to Synopsys Investor Day. We're so glad to have you here. It's great to see so many familiar faces in person rather than on Zoom. It's a very exciting day for all of us here at Synopsys, and we thank you for joining us in person and for those joining us online.
Before I go any further, I need to read a short legal disclosure. Synopsys will discuss forecasts, targets and other forward-looking statements during today's presentation. While these statements represent our best judgment as of today, they are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that may affect our future results are described in our most recent SEC filings.
We will refer to certain non-GAAP financial measures throughout today's presentation, and reconciliations
